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ABSTRACT OF THE DISSERTATION
Molecular Characterization of a Novel, Highly Protective Combination Monoclonal Antibody
Therapy against Chikungunya Virus
by
Pankaj Pal
Doctor of Philosophy in Biology and Biomedical Sciences
(Molecular Microbiology and Microbial Pathogenesis)
Washington University in St. Louis, 2015
Professor Michael Diamond, Chair

Chikungunya virus (CHIKV) is an Aedes mosquito-transmitted alphavirus that causes
epidemics of a debilitating, often chronic polyarthritis in humans. Over five million people in
Africa and Asia have been infected since 2005, and an outbreak occurred recently in Italy
demonstrating the potential for a global epidemic. A strong antibody response is elicited during
infection and the aim of this thesis was to develop a better understanding of how the humoral
immune response can control CHIKV infection. We identified 230 new anti-CHIKV monoclonal
antibodies (MAbs) and tested their ability to inhibit infection of strains representing all three
CHIKV genotypes (East/Central/South African, West African and Asian). We identified 36 of
these MAbs that inhibit Chikungunya infection; almost half of them are potently neutralizing and
have EC50 values of less than 15 ng/mL (0.1 nM) against CHIKV strains representing the three
genotypes. Many of these MAbs exhibit cross-reactivity with a number of related alphaviruses
including O’nyong’nyong, Ross River, Semliki Forest, Mayaro, Una, Getah, Bebaru,
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Middleburg, Barmah Forest, Sindbis and Venezuelan equine encephalitis viruses. Four of these
neutralizing MAbs provided complete protection as prophylaxis in highly susceptible
immunocompromised mice and mapped to distinct antigenic epitopes on the E1 and E2 structural
proteins. To define functional epitopes, we selected for escape mutants in vitro for these four
MAbs. We identified most of these escape mutants in the brains and leg muscle of mice dying
despite lower dose prophylaxis or monotherapy. The most protective MAb was humanized,
shown to block viral fusion, and require Fc effector function for optimal activity in vivo. In postexposure therapeutic trials, administration of a single dose of a combination of two neutralizing
MAbs targeting different domains of the E2 surface glycoprotein or targeting both the E1 and E2
glycoproteins limited the development of resistance and protected immunocompromised mice
against disease when given even 24 to 36 hours before CHIKV-induced death. These studies
provide some insight into the location of neutralizing epitopes of CHIKV and how selected pairs
of highly neutralizing MAbs may be a promising treatment option for CHIKV infection in
humans.
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Chapter I

Introduction

1

Virology and Structure of Chikungunya Virus

Chikungunya virus (CHIKV) is encoded by an 11.8 kb single-stranded, positive sense
RNA with two open reading frames (ORF). It is one of 29 alphaviruses and belongs to the
Togaviridae family of enveloped viruses. The Alphavirus genus is split into the New World
alphaviruses, which include Eastern, Western, and Venezuelan equine encephalitis viruses
and the Old World alphaviruses, which are primarily arthitogenic and include CHIKV,
Sindbis, Semliki Forest, Ross River and O’nyong’nyong viruses [1,2]. There are three
genotypes of CHIKV: East/Central/South African (ECSA), Asian and West African. Based
on E1 amino acid sequence analysis, the three genotypes are between 95.2 and 99.8%
identical [3]. The CHIKV genome is flanked by untranslated regions with a 5' N-methyl
guanosine cap and polyA tail, between which two ORFs reside. The 5' two-thirds of the
genome encodes the four non-structural proteins (nsP 1, 2, 3, 4) [4,5]. As shown for other
alphaviruses, it is predicted that two different non-structural polyproteins are translated. The
predominant population is nsP123 and a minor amount of nsP1234 is produced when there is
complete read-through of this ORF. As nsP4 is the RNA polymerase, limiting the production
of nsP4 can help control RNA replication. These polyproteins are subsequently processed
into the individual proteins by the nsP2 protease. The second ORF, which is downstream of
a separate 26S subgenomic promoter [6], encodes the structural proteins: C (the nucleocapsid
protein), E3, E2, 6K, and E1. [4,7]
Of the five structural proteins, the glycosylated envelope proteins E1 and E2 form
heterodimers in a trimeric array. Eighty such trimers compose the icosahedral lattice which is
embedded into a host plasma-membrane derived lipid bilayer by a single transmembrane
2

helix for each of E1 and E2. This constitutes the envelope and outermost layer of CHIKV.
Two-hundred and forty copies of the capsid protein also arrange into an icosahedral structure
to form the nucleocapsid layer (with T=4 symmetry), within which the ssRNA genome is
located. [7]
The E2 precursor protein, p62 is cleaved by the cellular enzyme furin en-route to the
plasma membrane to yield the mature E2 and E3 proteins. The small protein E3 is composed
of the 64 N-terminal amino acids of p62 and it remains attached to the virion on some
alphaviruses [8-10]. Glycoprotein E1 is composed of the N-terminal domain I and domains II
and III; the fusion loop is located at the tip of domain II. E2 is composed of domains A, B
and C. Domains III and C are oriented closest to the viral membrane. Recently, the crystal
structures of CHIKV p62-E1 and mature E3-E2-E1 were solved [8]. E2 covers much of E1 in
a twisted plate morphology on the viral surface and the fusion loop of E1 lies between the
groove formed by domains A and B of E2. These studies also indicate that the immature and
mature forms of the heterodimer are similar, except for the tether region connecting E3 to
p62, which is disordered in the mature post-furin cleavage form [8].

Epidemiology

Although Chikungunya virus was first isolated from a febrile patient during an epidemic
of fever and severe joint pain in Tanzania in 1953 [11-14], based on retrospective case-study
and phylogenetic analysis, it is estimated that CHIKV has caused disease in Africa and
Southeast Asia since the late 1700’s. CHIKV has epidemic potential, as reflected by the
initial description in which it spread from village to village, infecting between 80-90% of the
3

inhabitants [15]. Over the last few decades, CHIKV has re-emerged and periodically caused
outbreaks across Africa and Asia [1,16]. Significant morbidity has been observed, although
historically, infection did not cause much mortality. Between 2005 and 2007, however, there
was an explosive CHIKV epidemic of unprecedented magnitude; it initiated on the coast of
Kenya in 2004 and spread to the French island of La Reunion (LR), from which it quickly
dispersed to other Indian Ocean islands, India and many nations in Africa [1,17,18]. The
ECSA genotype of CHIKV gave rise to this epidemic strain of circulating CHIKV which
affected over five million people including approximately one third of the population of La
Reunion island (~300,000 people) [18,19]. Although travelers returning from endemic
countries to Canada, Europe and the United States have developed Chikungunya disease,
local epidemics did not occur in these temperate climates. This changed in 2007 with the
onset of the first European autochthonous epidemic, which caused 229 cases and one fatality
in Northern Italy [20-22]. Three years later, in 2010, autochthonous cases of Chikungunya
were reported in France [22,23]. This highlights the possibility of CHIKV spread across the
world and the importance of developing a vaccine or specific antiviral agents.
Vertical transmission of CHIKV also has been observed and results in peripartum disease
(4 days prior to or 2 days post delivery), likely due to intrapartum contamination of fetal
blood with CHKV, before the mother makes protective antibodies [24,25]. Studies estimate
that vertical transmission rates are 40 to 50% for viremic mothers [25-27]. These infants
require intensive care and have a high propensity for developing neurological symptoms.
[24,25]
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Clinical Disease of CHIKV infection

The word “chikungunya” comes from the Makonde language spoken in Tanzania and it
means “that which bends up”; this describes the contorted posture of patients afflicted with
this disease. Acute infection with CHIKV manifests three to seven days post transmission by
an Aedes mosquito bite. Symptoms include abrupt onset of a high fever, pruritic,
maculopapular rash (occurring in 40 to 50% of patients) which extends over the trunk and
limbs and sometimes the face, polyarthralgias (occurring in >95% of patients) and myalgias
(occurring in 90% of patients) [4,24,28-31]. Tenosynovitis is another common sign observed
in the chronic, recurring form of CHIK disease and most often affects the wrists, fingers and
ankles [32,33]. Polyarthralgias are mainly symmetric and tend to occur in previously injured
joints or distal joints [24]. Acute symptoms persist for about 14 days but chronic arthralgias
can linger and are a significant cause of morbidity for weeks to even years. Pain can fluctuate
in intensity, but does not usually change anatomical location. Joint pain is often debilitating;
a recent prospective study showed that arthralgias persisted for at least 36 months in over
60% of a cohort of patients [34]. Rheumatological manifestations, consisting of a febrile
arthritis predominantly affecting the extremities, were detected 15 months post-infection in
57% of another cohort of CHIKV patients, although there was no bone or cartilage erosion
[24,35,36]. Prior osteoarthritis, hypertension or age > 45 were identified as risk factors for
developing chronic joint manifestations [36].
Prior to the Indian Ocean outbreak, CHIKV infection was not associated with mortality
but in 2005, this and other severe disease manifestations surfaced. During the epidemic, ~250
deaths were attributed to CHIKV infection on the island of La Reunion, which corresponds
5

to one death per 1,000 infections [37-39]. Patients with atypical presentations, however, had
a death rate of 10% [26,27]. Some atypical manifestations included neurological
(encephalitis, meningoencephalitis, seizures, and Guillain-Barre syndrome), cardiac
(myocarditis, pericarditis, and heart failure) and renal (nephritis and acute renal failure)
[1,24,26,28,40] signs and symptoms.

Enzootic cycle

CHIKV is transmitted by the Aedes species mosquitoes and is maintained in a sylvatic
cycle in Africa, where non-human primates and rodents are the reservoirs and forest-dwelling
mosquitoes (chiefly the Aedes species furcier, taylori, luteocephalus and africanus) and are
the vectors for transmission. [4,41-43] During epidemics, humans serve as the reservoirs. In
Asia, there is only mosquito-human-mosquito transmission, as a sylvatic cycle has not been
documented [24,42]. Aedes aegypti, an urban mosquito that maintains close association with
humans, is the primary vector in Asia. In comparison, Aedes albopictus was the vector
primarily responsible for the La Reunion epidemic in 2005-2007 [1,4]. The global
distribution of Aedes albopictus mosquitoes has spread over the last few decades to include
all continents, either tropical or temperate, so CHIKV epidemics could theoretically occur
anywhere. [37]
An A226V mutation on the E1 glycoprotein served as a gain-of-function adaptive change
that resulted in enhanced infectivity of Aedes albopictus mosquitoes (via enhanced
dissemination of the virus from the midgut to secondary organs), which ultimately caused an
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increase in transmission of CHIKV to humans [4,24,44]. At the beginning of the outbreak, all
viral isolates possessed A226 on the E1 glycoprotein, whereas by the end of the epidemic
over 90% of CHIKV isolated from La Reunion had acquired the valine point mutation
[44,45]. The autochthonous cases of Chikungunya reported in Italy were caused by an
A226V isolate of CHIKV, but the autochthonous cases in Italy originated from the Asian
genotype and lacked this mutation [22]. Notably, the ratio of clinical apparent to inapparent
cases is high for CHIKV; only 3.2% of people tested in one study conducted on La Reunion
were seropositive for CHIKV yet failed to develop acute symptoms consistent with infection
[28].

Replication Cycle and Virus Assembly

Although the protein NRAMP was recently discovered as a necessary cell surface factor
for binding and entry of Sindbis virus, a related alphavirus, a bona fide entry receptor for
CHIKV has not been defined [46]. The E2 glycoprotein binds to the cell surface and this is
followed by internalization of CHIKV into endosomes, likely in a clathrin-dependent fashion
[47]. Upon acidification of the late endosome, the E1-E2 heterodimer dissociates and the E1
glycoprotein (which is a class II fusion protein) undergoes conformational changes exposing
the fusion loop [41,48]. E1 rearranges into homotrimers which induce fusion between the
viral and endosomal membranes, thus releasing the nucleocapsid into the cytoplasm
[8,10,48]. The CHIKV genome is an infectious RNA and can be translated immediately in
the cytoplasm [7] without modification. Following translation of the non-structural proteins
(nsP1, nsP2: the helicase, protease and protein also involved in host transcriptional shut-off,
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nsP3 and nsP4, the RNA polymerase) and replication of the genome to yield negative sense
RNA, the 3' 26S subgenomic RNA is produced and translated into a polyprotein, which is
autoproteolytically cleaved into the five structural proteins that form the virion [4]. After the
N-terminally located capsid protein is released from this polyprotein, pE2 and E1 are inserted
into the endoplasmic reticulum, form dimers and passaged through the Golgi apparatus. En
route to the plasma membrane, furin, a cellular calcium-dependent serine protease processes
pE2 into E2 and E3. These envelope proteins insert into the plasma membrane [5,38].
The nucleocapsid is composed of 80 copies of the capsid protein. It forms independently
in the cytoplasm and encloses a single copy of viral genomic RNA. CHIKV particles bud
from the plasma membrane as the nucleocapsid associates with the type I integral membrane
protein E2. Each budding particle contains 80 surface spikes, each composed of a trimer of
E1-E2 heterodimers arranged in T=4 quasi icosahedral symmetry [5,8].

Pathogenesis of CHIKV

Upon delivery of CHIKV into the skin, the virus spreads into the subcutaneous capillaries
and predominantly infects fibroblasts in the connective tissue [38,49]. It disseminates
through the blood to lymph nodes and can infect cells in other target organs, such as the liver,
spleen, muscle and joints [38,49]. CHIKV does not infect osteoclasts, osteoblasts,
lymphocytes or dendritic cells and there are contradictory reports on its infectivity of
monocytes [39,50]. CHIKV also selectively infects muscle satellite cells (but not myocytes),
endothelial cells and monocyte-derived macrophages. Muscle satellite cell infection has been
observed in patient biopsies and in vitro [51]. Muscle satellite cell infection is particularly

8

significant because these cells are progenitors for new muscle fibers and augmentation of
pre-existing muscle fibers; satellite cells will undergo cell division and differentiation after
exercise or muscle injury. If these muscle stem cells are infected, they may help maintain a
persistent reservoir of CHIKV in the muscle tissue, which may contribute to recurrent
episodes of arthralgias and myalgias [51,52].
CHIKV replicates efficiently in humans and titers can reach 1012 RNA copies/mL in the
serum of infected patients [53]. Tissues targeted in mouse and primate models and in human
patients include connective tissue, especially the muscle epimysium, the joint capsule, and
deep dermis [49,52]. Viral dissemination throughout the body was evidenced in a macaque
model of CHIKV infection, which recapitulates features of human disease. CHIKV RNA was
detected in the liver, spleen, lymph nodes and joints of all animals tested in the acute phase
and infectious CHIKV was still recovered from the spleen, muscle and liver 44 days post
infection [54]. Persistence of CHIKV antigen was detected in splenic macrophages up to 44
days post-infection and has been hypothesized to serve as a reservoir for long-term
persistence of CHIKV [54]. Identifying a potential chronic reservoir of CHIKV may be very
important for understanding the pathophysiology underlying chronic disease. Macrophages
may contribute to this reservoir; CHIKV was detected 18 months post-infection in the perivascular synovial macrophages of one patient [53]. Additionally, Binadarit (an inhibitor of
MCP-1) was shown to ameliorate arthritis-like disease symptoms in mice [55]. MCP-1
(monocyte chemotactic protein 1) is a crucial recruitment factor for macrophages into
inflamed sites and is unregulated in both the serum and tissue of CHIKV-LR infected mice
and acutely infected patients [53,55].
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In mouse models of CHIKV disease, lethality to CHIKV infection is both age and
IFNAR status-dependent [49]. IFNAR-/- C57BL/6 mice are highly vulnerable and will die
three days post intradermal infection with 10 PFU CHIKV-LR. Similarly, 6 day old C57BL/6
wild-type neonates will uniformly die when administered 106 PFU of CHIKV-LR
intradermally , but if they are allowed to age just three more days, 60% will survive and at 12
days of age these mice are no longer susceptible to death following CHIKV infection [49].
Although CHIKV is an Old World arthritogenic virus, it has been shown to cause CNS
disease, (encephalitis and meningitis), especially in neonatal patients and in mouse models
[26]. CHIKV infects the choroid plexus and ependymal cells and the meninges but not brain
endothelial cells, neurons, or microglia [49].

Antibody-mediated Protection against CHIKV

Polyclonal antibody response to CHIKV
Although the innate immune response plays an essential early role in protection against
CHIKV infection, the antibody response against this virus is rapid and also important. IgG
can be detected 3-8 days post symptom onset, even as early as 2 days post symptoms in some
patients [31,56,57]. Many patients in a study of travelers returning back to Europe from the
Indian Ocean region were positive for IgM antibody at the onset of symptoms (day 1) and all
patients positive for CHIKV infection had both IgG and IgM by day 5 post symptom onset
[57]. The rapid kinetics of antibody production may, in part, be attributed to the high CHIKV
viremia, which results in a significant antigen load prior to symptom onset,[57]. Although
IgM titers usually last for 1-3 months post-infection [31]; the persistence of IgM as late as 18
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months after acute CHIKV infection in some patients suggests possible viral persistence
[35,58].
The importance of the antibody response in clearing CHIKV infection was demonstrated
in µMT mice that lack mature B cells. These mice sustain significantly higher CHIKV titers
that start earlier in the course of disease, and they experience more joint swelling than wild
type mice. Chronic infection occurred in µMT mice; viremia persisted for 79 days and has
lasted as long as 402 days in surviving mice [59].
Passive transfer of polyclonal immunoglobulins from convalescent CHIKV infected
patients protect against death of CHIKV-infected immunocompromised or neonatal mice.
This demonstrates the neutralizing and protective potential of immune sera [60]. In a separate
study, non-human primates were vaccinated with virus-like-particles (VLPs) containing
CHIKV structural proteins; two milligrams of purified IgG from these animals was delivered
passively to IFNAR-/- mice; this protected against death and viremia [61]. This further
suggests that antibodies in immune sera alone can protect against CHIKV infection.

Monoclonal antibody response to CHIKV
Only a few studies involving CHIKV MAbs have been reported. Mouse MAbs against
CHIKV that cross-react to O’nyong’nyong virus, some of which inhibit haemagglutination of
both CHIKV and O’nyong’nyong virus, were identified in 1995 [62]. Years later, another
study identified three antibodies that were shown to react with the E2 glycoprotein of
CHIKV; neutralization potential was not determined [63].
Two neutralizing human MAbs (8B10 and 5F10) were identified from immortalized
peripheral blood mononuclear cells (PBMCs) harvested from a patient previously infected
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with CHIKV [64]. Escape mutants that were less sensitive to neutralization by these MAbs
were isolated under antibody passage, but they still partially neutralized at higher
concentrations of MAb [65]. The potential of one of these mutations (E2-R82G) to enhance
potential cell-cell transmission of CHIKV was considered [65], however, further study is
warranted. Although a high dose (250 µg) of 8B10 was protective against death in AGR129
mice (lacking the interferon α/β/γ receptor) when administered six hours before CHIKV
infection, neither 8B10, 5F10 or the combination of these MAbs was able to prevent death
therapeutically even when delivered just eight hours post infection [66].
Studies investigating the human antibody response to CHIKV have suggested that the
dominant, neutralizing antibodies produced are mostly directed against the E2 glycoprotein
and the major isotype represented is IgG3 [59,67-69]. One study found that neutralizing
human antibodies primarily target a linear peptide consisting of 18 amino acids located at the
N-terminus of E2 which they denoted E2EP3 [67]. In a different cohort consisting of nine
patients, antibodies targeting nsP3 and E2 were identified 2-3 months post-infection, but only
antibodies against E2 persisted 21 months post infection [69].
Patient studies also have correlated a more severe, acute disease with early, high viremia
but this group also developed an early IgG3 response and completely cleared CHIKV
infection without persistent arthralgia [68]. Early IgG3 responders were defined as patients
producing IgG3 by 7- 10 days after the onset of infection and while no one in this group
maintained chronic CHIKV symptoms, 30% of late IgG responders developed persistent
arthrlagias [68].

12

Rationale
This work was initiated towards the end of one of the largest recorded CHIKV
epidemics in history, when little was known about the immune response to CHIKV. We
sought to generate a novel panel of anti-CHIKV MAbs because we were interested in
developing a better understanding of how the humoral immune system restricts CHIKV
infection. To encourage the diversity of epitopes targeted by MAbs, we immunized mice
with CHIKV-LR and boosted four mice with either VLPs [61], E2 glycoprotein or CHIKVLR. We aimed to identify highly neutralizing MAbs, determine what viral epitopes they
targeted, identify mechanisms of neutralization and determine if these MAbs are protective in
animal models. There is currently no licensed, human vaccine for CHIKV but insight into
neutralizing viral epitopes is imperative for directed vaccine design so we hoped to learn
more about neutralizing CHIKV epitopes and the molecular basis of neutralization.
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ABSTRACT
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes
global epidemics of a debilitating polyarthritis in humans. As there is a pressing need for
the development of therapeutic agents, we screened 230 new mouse anti-CHIKV
monoclonal antibodies (MAbs) for their ability to inhibit infection of all three CHIKV
genotypes. Four of 36 neutralizing MAbs (CHK-102, CHK-152, CHK-166, and CHK263) provided complete protection against lethality as prophylaxis in highly susceptible
immunocompromised mice lacking the type I IFN receptor (Ifnar-/-) and mapped to
distinct epitopes on the E1 and E2 structural proteins. CHK-152, the most protective
MAb, was humanized, shown to block viral fusion, and require Fc effector function for
optimal activity in vivo. In post-exposure therapeutic trials, administration of a single
dose of a combination of two neutralizing MAbs (CHK-102 + CHK-152 or CHK-166 +
CHK-152) limited the development of resistance and protected immunocompromised
mice against disease when given 24 to 36 hours before CHIKV-induced death. Selected
pairs of highly neutralizing MAbs may be a promising treatment option for CHIKV in
humans.

21

AUTHOR SUMMARY
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes
outbreaks of polyarthritis in humans, and is currently a threat to spread to the United
States due to the presence of its mosquito vector, Aedes albopictus. At present, there is no
licensed human vaccine or therapeutic available to protect against CHIKV infection. The
primary goal of this study was to develop an antibody-based therapeutic agent against
CHIKV. To do this, we developed a panel of 230 new mouse anti-CHIKV MAbs and
tested them for their ability to neutralize infection of different CHIKV strains in cell
culture. We identified 36 MAbs with broad neutralizing activity, and then tested several
of these for their ability to protect immunocompromised Ifnar-/- mice against lethal
CHIKV infection. In post-exposure therapeutic trials, administration a single dose of a
combination of two neutralizing MAbs limited the development of resistance and
protected Ifnar-/- mice against disease even when given just 24 to 36 hours before
CHIKV-induced death. Analogous protection against CHIKV-induced arthritis was seen
in a disease model in wild type mice. Our data suggest that pairs of highly neutralizing
MAbs may be a therapeutic option against CHIKV infection.
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INTRODUCTION
Chikungunya virus (CHIKV) infection causes a severe febrile illness in humans
that is characterized by a debilitating polyarthritis, which can persist for months and
cause significant morbidity [1,2]. There are three genotypes of CHIKV: Asian,
East/Central/South African (ECSA), and West African [3-5], with 95.2 to 99.8% amino
acid identity [4]. The CHIKV strains from the recent epidemics belong to the ECSA
genotype and have affected millions in Africa and the Indian subcontinent [3,6]. Imported
cases in the United States and outbreaks in Europe highlight the threat of CHIKV to
developed countries [7]. Currently, there are no approved vaccines or therapeutics for
CHIKV [8].
CHIKV is an enveloped alphavirus of the Togaviridae family that enters cells via
receptor-mediated internalization and a low pH-triggered type II membrane fusion event
in early endosomes. The mature virion is comprised of three structural proteins: a
nucleocapsid protein and two glycoproteins, E1 and E2, where E2 functions in
attachment to cells and E1 participates in virus fusion. Each 700 Å CHIKV virion
contains 240 copies of the envelope and capsid proteins, which are arranged in T=4
quasi-icosahedral symmetry. E1-E2 heterodimers assemble into 80 trimeric spikes on the
virus surface [9]. X-ray crystallographic structures of the precursor pE3-E2-E1, mature
E2-E1, and E1 proteins [10-13] have elucidated the architecture of the glycoprotein shell.
The E1 ectodomain consists of three domains. Domain I (DI) is located between DII and
DIII, the latter of which adopts an immunoglobulin-like fold. The fusion peptide is
located at the distal end of DII. E1 monomers lie at the base of the surface spikes and
form a trimer around each of the icosahedral axes. E2 localizes to a long, thin leaf-like
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structure on the top of the spike. The mature E2 protein contains three domains with
immunoglobulin-like folds: the N-terminal domain A, located at the center; domain B at
the tip; and the C-terminal domain C, located proximal to the viral membrane.
Mouse models have been developed for CHIKV infection. Newborn outbred and
inbred mice are vulnerable to severe CHIKV infection with viral replication observed in
muscle, joint, and skin [14,15]. Adult mice with defects in type I interferon signaling
(Ifnar-/- mice) develop lethal disease, with muscle, joint, and skin appearing as the
primary sites of infection [15]. CHIKV infection of juvenile C57BL/6 mice by a
subcutaneous route results in metatarsal foot swelling with histological evidence of
arthritis, tenosynovitis and myositis [16,17].
Passive transfer of MAbs or immune sera can protect animals against infection of
alphaviruses including Sindbis (SINV), Semliki Forest (SFV), and Venezuelan equine
encephalitis (VEEV) viruses [18-25]. Immune -globulin from human donors in the
convalescent phase of CHIKV infection exhibited neutralizing activity in vitro and had
partial therapeutic efficacy in Ifnar-/- and neonatal wild type mice when administered up
to 24 hours after infection [26]. Although mouse and human MAbs that neutralize
CHIKV infection have been reported [27,28], their post-exposure efficacy against lethal
infection in vivo has not been clearly established [29].
Here, we investigated the molecular basis of antibody-mediated neutralization of
CHIKV using a panel of 230 newly generated, cloned MAbs. CHK-152 protected mice
against CHIKV-induced mortality and disease. The inclusion of a second MAb (CHK166 or CHK-102) prevented the emergence of viral resistance and extended the treatment
window in Ifnar-/- mice up to 24 to 36 hours prior to death of the animals. Our results
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suggest that combination therapy with selected neutralizing MAbs has potential for
treatment of CHIKV infection in humans.
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RESULTS
Generation of MAbs. We generated a panel of neutralizing MAbs against
CHIKV as a first step towards a possible therapy in humans. We infected adult C57BL/6
mice deficient for interferon regulatory factor 7 (Irf7-/-) with 104 PFU of the La Reunion
2006 OPY-1 strain of CHIKV (CHIKV-LR); these mice were boosted with CHIK viruslike particles [30], soluble recombinant CHIKV E2 protein, or live CHIKV-LR. We
immunized Irf7-/- rather than wild type (WT) mice, as CHIKV replicated to higher titers,
induced stronger neutralizing antibody responses, yet did not cause lethal infection in
these innate immune-deficient animals ([31], and data not shown). We screened four
independent myeloma cell-splenocyte fusions for binding of hybridoma supernatants to
CHIKV-LR infected cells (Fig S1) and cloned 230 CHIKV-specific MAbs for further
analysis (Table S1 in Text S1). Using a single endpoint neutralization assay, we
identified 36 MAbs with inhibitory activity against infection of CHIKV-LR in BHK2115 cells (data not shown).
Neutralizing activity. To assess the inhibitory potential of our anti-CHIKV
MAbs against the homologous CHIKV-LR and representative strains from the Asian and
West African genotypes (RSU1I and bH35respectively), we performed focus reduction
neutralization tests (FRNTs) on Vero cells. We determined the concentration of MAb that
reduced the number of foci of infection by 50 or 90% (EC50 and EC90 values, Fig 1A
and B, and Table 1). CHK-152 was the most strongly neutralizing MAb we identified; 3
and 15 ng/ml of this MAb prevented 50 and 90% of CHIKV infection against all three
CHIKV genotypes (Fig 1C). Ten other MAbs inhibited CHIKV infection with EC50
values of <10 ng/ml against all three genotypes, and many others inhibited all three
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strains similarly, with a few exceptions. For example, CHK-9 failed to neutralize the
Asian strain to the same extent as the West African or La Reunion (ECSA genotype)
strains (Fig 1D), whereas CHK-151 inhibited infection of the Asian strain better than the
others (Table 1). Also, for reasons that are unclear, some neutralizing MAbs (e.g., CHK143, CHK-264, and CHK-269) were incapable of inhibiting all viruses (EC90 > 10,000
ng/ml) in this assay, even at high MAb concentrations.
We speculated that some MAbs might show cell type-dependent neutralization if
they blocked attachment to cell type-specific factors. To test this hypothesis, we assessed
MAb neutralization of CHIKV-LR infection in cells of another species, NIH 3T3 mouse
fibroblasts (Table 1). For most MAbs, the EC50 values were comparable to those
achieved with Vero cells. However, two MAbs (CHK-96 and CHK-176) showed a 12 to
250-fold reduction (P < 0.05) in neutralizing activity on NIH 3T3 compared to Vero
cells; although further study is warranted, these MAbs may block a step in the entry
pathway that varies among different cell types.
Prophylaxis studies. To evaluate whether neutralizing MAbs protect against
CHIKV infection in vivo, we initially used a stringent test model: prevention of lethal
infection in immunodeficient Ifnar-/- C57BL/6 mice. One hundred micrograms of 14
different MAbs with strong, modest, or poor neutralizing activity were administered to
Ifnar-/- mice one day prior to CHIKV-LR infection. As seen previously [15], all Ifnar-/mice died by day 4 after infection when treated with saline or a negative control MAb
(Fig 2A, and data not shown). Strongly neutralizing (e.g., CHK-102, CHK-152, and
CHK-263) and one moderately inhibitory (CHK-166) MAb protected 100% of mice from
lethal infection (P < 0.0001). In comparison, and somewhat surprisingly, CHK-95, a

27

potently neutralizing MAb of the same IgG2c isotype, protected only 12% of mice from
death. The other MAbs tested conferred intermediate levels of protection (Fig 2A). Thus,
although several strongly neutralizing MAbs prevented against lethal CHIKV infection in
Ifnar-/- mice, in vitro neutralization activity per se did not directly correlate with
protection. To define the relative potency of the four MAbs that completely prevented
lethal disease, we administered a lower (10 µg) dose. Whereas CHK-152 and CHK-263
still protected most mice from lethal infection, CHK-102 and CHK-166 protected to a
lesser degree or only prolonged survival (Fig 2B). Consistent with their ability to protect
against lethal infection, passive transfer of CHK-102, CHK-152, CHK-166, and CHK263 MAbs all markedly reduced viral loads in serum, spleen, liver, muscle, and brain at
48 hours after infection relative to a non-binding isotype control (DENV1-E98) MAb
(Fig 2C-G). The level of protection afforded by CHK-102, CHK-152, CHK-166, and
CHK-263 MAbs, however, did not correlate directly with their binding strength to
CHIKV surface glycoproteins (Fig S2).
Although a stringent test of MAb protection, CHIKV-infected Ifnar-/- mice do not
develop the arthritis observed in humans. To evaluate this, we utilized a WT C57BL/6
mouse model in which inoculation of CHIKV into the footpad results in localized
swelling and induction of arthritis and fasciitis within the foot and ankle [16,17],
although infection does not cause lethality. Pretreatment of mice with either 100 µg of
CHK-102 or CHK-152 completely protected against CHIKV-induced swelling, compared
to control animals, which developed clinically apparent swelling (data not shown). While
CHIKV infected control animals developed inflammatory arthritis in the ankle and foot,
CHK-102 or CHK-152 MAb treated animals had normal appearing joint tissues (Fig 2H).
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Mechanism of neutralization. Antibody neutralization of enveloped viruses can
occur by inhibiting attachment, internalization, and/or fusion [32,33]. To determine how
many of our most protective MAbs inhibited infection in cell culture, we performed preand post-attachment neutralization assays [34,35]. Anti-CHK MAbs were incubated with
CHIKV before or after virus binding to cells, and infection was measured. As expected,
all MAbs efficiently neutralized infection when pre-mixed with virus (Fig 3A). While
CHK-102, CHK-152, CHK-166, and CHK-263 also inhibited CHIKV infection when
added after virus adsorption to the cell surface, suggesting that at least part of their
blocking activity was at a post-attachment step, differences in the extent of neutralization
were noted in this context for several MAbs. CHK-152 completely neutralized all
CHIKV virions without a resistant fraction when added post-attachment. When studies
were repeated with eight other neutralizing MAbs that showed pre-exposure protection in
vivo, no other MAb inhibited infection completely when added after virus adsorption to
the cell. As expected, an isotype control MAb (DENV1-E98) and a non-neutralizing antiCHK MAb (CHK-84) had no inhibitory effects in this assay (Fig S3).
Blockade of viral fusion. Since CHK-152 neutralized infection efficiently at a
post-attachment step, we investigated whether it blocked fusion using a viral fusion from
without (FFWO) assay [36]. CHIKV was adsorbed to Vero cell monolayers on ice and
then treated with MAbs. Fusion at the plasma membrane was triggered after a brief
exposure to low pH buffered medium at 37°C. Subsequently, cells were incubated in the
presence of 20 mM NH4Cl to prevent CHIKV fusion via canonical endosomal pathways.
As expected, at 14 hours after initial treatment, CHIKV infection was not observed when
adsorbed virus was incubated at neutral pH (Fig 3B). In comparison, in the absence of
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MAb or in the presence of a control MAb, a short exposure of cell surface-adsorbed virus
to acidic pH resulted in infection and CHIKV-antigen positive cells. Notably, CHK-152
completely inhibited (P < 0.0001) plasma membrane fusion and infection, whereas other
anti-CHIKV neutralizing MAbs showed significant yet incomplete inhibition in this assay
(Fig 3B and C). These studies suggest that CHK-152 efficiently neutralizes infection by
preventing the structural changes on the virion necessary for viral fusion with host cell
membranes.
We utilized a model liposome fusion assay with pyrene-labeled virus [37,38] to
confirm these results. Pyrene-labeled CHIKV was pre-incubated with different
concentrations of MAb, mixed with liposomes at 37°C, and fusion was triggered by
addition of a low-pH buffer [37]. In the absence of MAb or in the presence of 10 nM (1.5
µg/ml) of a non-binding control MAb, fusion was complete within seconds of
acidification. In contrast, pre-incubation of virus with increasing doses of CHK-152
inhibited fusion (Fig 3D and E). Thus, CHK-152 can block low-pH-induced fusion of
virus with liposomes.
The effector functions of CHK-152 contribute to protection in vivo. To define
additional mechanisms by which our most strongly protective MAb (CHK-152) conferred
protection in vivo, we generated a chimeric mouse-human CHK-152 (ch-CHK-152) as
well as an aglycosyl variant (ch-CHK-152 N297Q) that lacks the ability to engage C1q or
Fc-γ receptors; this mutation does not affect the ability to bind the neonatal Fc receptor
(FcRn) or half-life of antibody in mouse serum [39]. The affinity of ch-CHK-152 and chCHK-152 N297Q binding to purified pE2-E1 was measured by surface plasmon
resonance (SPR) and compared to the parent murine MAb. Notably, ch-CHK-152, ch-
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CHK-152 N297Q, and the murine CHK-152 all had similar affinity (KD of 3 to 4 nM)
(Fig 4A and data not shown) and neutralizing activity in cell culture (Fig 4B). As
expected, ch-CHK-152 N297Q failed to bind efficiently to soluble Fc-γ receptors or C1q
(Fig 4C).
We transferred ch-CHK-152 and ch-CHK152 N297Q to Ifnar-/- mice prior to
infection. Although high doses (100 µg) of ch-CHK-152 and ch-CHK-152 N297Q
provided similar protection against CHIKV infection (data not shown), lower doses (10
µg) of the aglycosyl variant were less protective; whereas 62% of the mice receiving chCHK152 N297Q survived, all Ifnar-/- mice given ch-CHK-152 MAb remained alive (Fig
4D, P < 0.05). When parallel studies were performed with WT C57BL/6 mice and MAb
was administered 18 hours after infection, ch-CHK-152 N297Q also provided less
protection against arthritis compared to ch-CHK-152 (Fig 4E). These data suggest that
the Fc effector interactions contribute to the potency of CHK-152 in mice.
Humanization of CHK-152. We humanized CHK-152 as a first step towards a
MAb therapeutic (see Supplemental Methods). The affinity for pE2-E1 and neutralizing
activity of the hu-CHK-152 were similar to mouse CHK-152 (Fig S4A and B). Hu-CHK152 also protected Ifnar-/- mice (P > 0.0001) when a single dose (10 or 100 µg) was
administered one day before infection (Fig S4C).
Therapeutic studies. To define the therapeutic potential of our most protective
MAbs, a single dose (100 µg) was administered to Ifnar-/- mice 24 hours after CHIKV
infection (Fig 5A). Whereas CHK-152 and 166 protected 58% and 63% of mice from
death, respectively (P < 0.0001), CHK-263 and CHK-102 had less activity although both
MAbs increased the median survival time (7 days versus 4 days with the control DENV1-
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E98 MAb, P < 0.0006). Administration of CHK-152 at 12 or 18 hours post infection also
protected WT mice from CHIKV-induced swelling and arthritis (Fig 5B and Fig 4E).
We next tested the activity of combinations of the most protective neutralizing
MAbs in Ifnar-/- mice. Remarkably, administration of 50 µg each (100 µg total dose) of
CHK-102 + CHK-152, CHK-263 + CHK-152, or CHK-166 + CHK-152 at 24 hours post
infection completely prevented mortality in all animals (Fig 5A, P < 0.0001 for MAb
combinations). This observation was not true for all MAb combinations, as
administration of 50 µg each of CHK-102 + CHK-263 provided substantially less
protection with a 14% survival rate. We then performed a more stringent test in which
100 µg each (200 µg total) of our most protective combinations was delivered as a single
dose at 48 hours post-infection (Fig 5C). Treatment with CHK-102 + CHK-152 or CHK166 + CHK-152 protected 62% of the Ifnar-/- mice (P < 0.003) and the combination of
CHK-263 + CHK-152 functioned almost as well, with 50% of animals surviving (P <
0.03). To define the limits of protection in Ifnar-/- mice, which all succumb to CHIKV
between days 3 and 4, therapy was initiated at 60 and 72 hours after infection. At 60
hours after infection, Ifnar-/- mice receiving 250 µg each of CHK-102 + CHK-152 or
CHK-166 + CHK-152 had survival rates of 28 and 71%, respectively (Fig 5D, P = 0.03
and P = 0.004). Nonetheless, when combination therapy was given at 72 hours after
infection, a time when overt disease was present, no survival benefit was conferred. Thus,
combination MAb therapy is superior to monotherapy in protecting against lethal CHIKV
infection in highly immunocompromised mice.
Functional interaction of MAbs. To begin to understand the basis for enhanced
in vivo activity, we assessed whether CHK-152 and selected MAbs could bind
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simultaneously to the CHIKV virion. We developed a competition ELISA in which
virions were captured by a mouse MAb (CHK-65), and then incubated with increasing
concentrations of CHK-102, CHK-152, CHK-166, or CHK-263 mouse MAbs. After
washing, hu-CHK-152 MAb was added, and binding was assessed. While pre-bound
mouse CHK-152 competed against hu-CHK-152 binding as expected, CHK-102, CHK166, and CHK-263 minimally competed hu-CHK-152 binding (Fig S5A), suggesting
their epitopes largely were distinct. However, addition of CHK-102, CHK-166, or CHK263 failed to augment the inhibitory activity of CHK-152 when neutralization was
measured in cell culture (Fig S5B), as no synergy was observed.
Neutralization escape mutants. To identify epitopes targeted by the therapeutic
MAbs, we generated escape mutants in cell culture. After sequential virus passage under
CHK-102, CHK-152, CHK-166, or CHK-263 selection, CHIKV became resistant to
neutralization by these MAbs (Fig 6A-D). We assessed whether the escape variants
generated in the presence of one MAb remained sensitive to neutralizationby the other
MAbs. The CHK-152 escape variant was neutralized efficiently by CHK-102, CHK-166,
and CHK-263 (Fig 6B, Table S2 in Text S1, and data not shown), and analogously the
CHK-166 escape variant was inhibited by CHK-102, CHK-152, and CHK-263 (Fig 6C,
and data not shown). In contrast, CHK-102 and CHK-263 escape variants reciprocally
were resistant, suggesting their epitopes were the same or overlapping (Fig 6A and D);
however, CHK-102 and CHK-263 escape variants remained sensitive to neutralization by
CHK-152 and CHK-166. Notably, selection with combinations of MAbs (e.g., CHK-102
+ CHK-152) failed to produce escape variants despite several independent attempts (data
not shown).
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To identify the mutations that conferred resistance, we sequenced plaque-purified
escape variants (Table 2, top). Six of eight sequences from CHK-102 escape variants
contained an L210P mutation in the E2 protein; the remaining two sequences had a
G209E mutation in E2. For CHK-152 resistant variants, all sequences (9 of 9) contained a
D59N mutation in E2 and two contained a second A89E substitution in E2. For CHK263, 3 of 4 escape variants had a K215E change in E2, whereas 1 of 4 had mutations in
E2 at G209E. All escape variants (14 of 14) of CHK-166 had a single K61T mutation in
the E1 protein.
To verify the amino acid changes that conferred MAb resistance in vitro, we
introduced several of these substitutions into a chimeric SFV-GFP-CHIKV cDNA
comprised of SFV non-structural genes, a GFP reporter gene, and the CHIKV structural
genes (T. Lin, K. Dowd, and T. Pierson, unpublished results). Parental and SFV-GFPCHIKV with single amino acid mutations were analyzed for neutralization by CHK-102,
CHK-152, CHK-166, and CHK-263 (Fig 6E-H). Consistent with our sequencing results,
viruses encoding mutations in E2-G209 and E2-L210 were resistant to CHK-102,
changes in E2-D59 conferred resistance to CHK-152, substitutions in E1-K61 resulted in
resistance to CHK-166, and mutation of E2-G209 and E2-K215 caused resistance to
CHK-263. However, introduction of E2-A89E (which was present in 2 of 9 clones) failed
to affect the neutralizing activity of CHK-152.
In addition to selecting escape variants in cell culture, we harvested organs from
the few mice that became ill after infection despite single MAb treatment (Table 3,
bottom). In these moribund Ifnar-/- mice, CHIKV was present in the brain and muscle but
absent from the spleen or liver (data not shown). This in vivo-derived virus was tested for
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MAb resistance and sequenced. For mice receiving a 10 µg dose of CHK-102 as
prophylaxis, resistant variants with a L210P mutation in E2 were obtained. For mice
receiving CHK-263 or CHK-102 at 24 hours post infection, resistant viruses with a
G209E mutation in E2 were identified. None of the animals that were pre-treated with 10
µg of CHK-166 developed escape mutants, as the virus harvested from all 3 mice tested
retained sensitivity to CHK-166 (data not shown). However, in one animal receiving
CHK-166 at 24 hours post infection, a single resistant virus with a G64S substitution in
the E1 gene was recovered (Fig S6). For mice receiving a 10 µg dose of hu-CHK-152 as
prophylaxis, partially resistant viruses with N231D and K233E mutations in E2 were
isolated and confirmed by reverse genetics using the chimeric SFV-GFP-CHIKV
infectious clone (Fig S7). In comparison, when CHK-152 was given as a therapeutic, a
single mutation at D59N in E2 was obtained in 4 of the 5 mice tested, with a K233T
mutation in virus from the remaining animal. For animals treated at 48 hours with
combination MAb therapy, all recovered viruses remained sensitive to CHK-152 yet
showed partial resistance to CHK-102 or CHK-166 (Fig S8). Mutations in E2 (N332I,
CHK-166 + CHK-152) were identified. Comparison of 140 available E1 and E2
sequences from historical and circulating CHIKV strains in a public database
(http://www.viprbrc.org/) revealed nearly complete conservation of the residues in which
escape mutants were selected: E1-K61, 100%; E1-G64, 100%; E2-D59, 100%; E2-G209,
100%; E2-L210, 99.3%; E2-K215, 100%; E2-N231, 100%; and E2-K233, 99.3%.
To define spatially the location of the amino acids that conferred resistance to our
highly protective MAbs, these residues were mapped onto the existing CHIKV protein
crystal structures [10] (Fig 6I, left). Amino acids that conferred neutralization escape to
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CHK-102 and CHK-263 were located in the B domain of E2. The residues that
modulated CHK-152 neutralization mapped to the A domain of E2. In contrast, CHK-166
recognized amino acids on DII of E1, adjacent to the fusion loop. All amino acids that
conferred neutralization escape appear solvent accessible and highly exposed when
docked onto the E2-E1 spike (Fig 6I, right).
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DISCUSSION
We set out to identify MAbs with the greatest therapeutic activity against CHIKV
in mice as a first step toward generating an immunotherapy for humans. Thirty-six MAbs
with neutralizing activity against CHIKV-LR were identified, the majority of which also
inhibited infection of strains corresponding to the two heterologous CHIKV genotypes.
Although all fourteen of the selected anti-CHIKV MAbs improved outcome in vulnerable
Ifnar-/- mice, only four of these (CHK-102, CHK-152, CHK-166, and CHK-263)
completely prevented lethality when administered as prophylaxis. CHK-152 provided the
greatest benefit as post-exposure therapy, although by itself, the window of treatment
activity was limited in the Ifnar-/- mouse model. While addition of a second MAb (CHK102, CHK-166, or CHK-263) failed to enhance CHK-152 neutralization in vitro, it
limited the development of viral resistance in vitro and in vivo. Remarkably,
combinations of CHK-102 + CHK-152 or CHK-166 + CHK-152 protected Ifnar-/- mice
against mortality even when a single dose was administered 24 to 36 hours prior to the
death of untreated or isotype control MAb-treated animals.
In comparison to the highly therapeutic activity of 0.5 mg of CHK-152 + CHK166, a single 25 mg dose of immune IgG purified from a convalescent human subject
protected only 50% of Ifnar-/- mice when administered 24 hours after CHIKV infection
[26]. The administered dose of neutralizing antibody likely is critical to post-exposure
treatment of CHIKV infection because of the high viral burden [14,16,17,40]. A high
viral load impacts therapeutic activity of antibodies as it (a) increases the chance for preexisting or selected resistant variants to emerge through quasispecies [28,41]; and (b)
results in a low relative fractional occupancy of binding to any individual virion, which
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allows antibodies recognizing key epitopes to fall below their stoichiometric threshold of
neutralization [42]. Although there is extensive literature on the protective efficacy of
MAbs or immune sera against alphavirus infection [18-25], no prior study has
demonstrated reduced CHIKV-induced mortality with MAbs. Although a recent study
showed that combination post-exposure therapy with two human anti-CHIKV MAbs
(5F10 and 8B10, 250 µg each at + 8 h) prolonged survival of AG129 (Ifnar-/- x Ifngr-/-)
mice by ten days, they failed to prevent lethal infection [29]; the basis of this treatment
failure remains unclear but could reflect the lower neutralizing potency of the MAbs
(compared to CHK-152), rapid emergence of resistant mutants, or the relative
susceptibility of the immunocompromised mouse host. In comparison, a neutralizing
MAb (UM 5.1) administered two days after SFV infection completely protected
immuocompetent BALB/c mice [43].
Why were some combinations of two MAbs effective in vivo? (a) Pairs of MAbs
may show neutral, additive, or synergistic effects on neutralization. Positive antiviral
effects could occur through cooperative binding or by trapping CHIKV in conformations
that makes it less competent to bind a receptor or fuse with host membranes. Nonetheless,
when we added increasing concentrations of CHK-102, CHK-166, or CHK-263 to CHK152, we failed to observe synergy. (b) Certain MAb combinations could prevent the
emergence of resistance due to the low frequency of two escape mutations occurring
simultaneously in a single replication cycle. Although we could readily select for
neutralization escape against a single MAb in vitro and in vivo, we failed to isolate
resistant mutants against CHK-152 when two MAbs (e.g., CHK-102 + CHK-152) were
combined. However, some viruses from moribund animals treated with combination
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MAb therapy showed reduced sensitivity (up to 200-fold) to the other MAb (e.g., CHK102) in the pair. In comparison, when mice were treated with a combination of 50 µg
each of CHK-102 + CHK-263, we failed to observe the same survival benefit that was
conferred by the combinations of CHK-102, CHK-166, or CHK-263 with CHK-152.
Since CHK-102 and CHK-263 appear to share overlapping footprints on domain B of E2,
this particular MAb combination may fail to prevent the rapid emergence of escape
mutants relative to others targeting distinct epitopes on E1 and E2 proteins. (c)
Combinations of MAbs could select for resistant viruses that have reduced fitness [44],
and thus are less pathogenic in vivo. Virulence studies with CHIKV encoding selected
single and double mutations are planned to evaluate this possibility.
We localized the epitopes of our four highly protective MAbs using neutralization
escape selection, sequencing, and reverse genetics. CHK-152, which blocked viral fusion,
mapped to the wings of the A domain on E2, a result that we recently confirmed by cryoelectron microscopic analysis of CHK-152 Fab-virus particle complexes [45]. This
epitope also was identified as a recognition site for neutralizing MAbs against VEEV
[46] and SINV [47]. CHK-166, which was the least neutralizing (EC50 of ~100 ng/ml) of
our highly protective MAbs mapped to an epitope in domain II of the E1 protein, adjacent
to the highly conserved fusion loop. While anti-E1 MAbs against SINV and VEEV that
protect or neutralize infection have been described [46,48,49], none have been
characterized against CHIKV. A neutralizing human MAb (8B10) against CHIKV was
reported with possible reactivity against E1, although further analysis revealed that it
bound to the E1/E2 heterodimer [27,28]. CHK-102 and CHK-263 mapped to residues
within the B domain on E2. A related epitope also was identified in mapping studies of
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strongly neutralizing antibodies against Ross River virus [50], SINV [51,52], VEEV
[46,53,54], and CHIKV [10,28]. The B domain on E2 comprises an important antigenic
domain that is under selective pressure for antibody neutralization [41]. It serves as a cap
to the fusion loop on E1 and because of its location at the tip of the heterodimeric spike
[10,11] may contribute to attachment of cellular receptors.
In summary, we identified combinations of MAb pairs that were highly effective
as post-exposure therapeutic agents. These findings are consistent with recent studies
showing enhanced post-exposure efficacy of MAb combinations against Ebola [55],
influenza A [56] and rabies [57] viruses. Our most promising pair of MAbs mapped to
distinct epitopes, limited the generation of resistance, blocked multiple stages of the viral
entry pathway, and protected Ifnar-/- mice against mortality even when administered 60
hours after infection. CHK-152 was humanized as a first step towards a possible
therapeutic for humans and demonstrated similar efficacy compared to the parent murine
MAb. Tailored combinations of potently neutralizing MAbs show promise to prevent or
treat infection by CHIKV, and likely other pathogenic alphaviruses in humans.
Ultimately, a more detailed kinetic analysis of CHIKV infection in humans and
determination of a treatment window relative to symptom onset is warranted to establish
whether combination MAb therapy can prevent or mitigate acute or chronic and
persistent infection and joint disease.
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METHODS
Cells and viruses. Vero, Vero76 (ATCC), BHK21-15, and NIH 3T3 mouse
fibroblast cells were cultured in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 5% or 15% (for 3T3 cells) fetal bovine serum (FBS) (Omega
Scientific). C6/36 Aedes albopictus cells were grown in Leibovitz-15 medium
supplemented with 10% FBS at 27oC. The infectious clones of CHIKV La Reunion 2006
OPY-1 (strain 142, CHIKV-LR) and CHIKV-GFP (strain 145) were gifts from S. Higgs
(Manhattan, KS) [58]. CHIKV-RSU1 and CHIKV-IbH35 were gifts of R. Tesh,
(Galveston, TX). Infection studies of WT mice used the SL15649 strain of CHIKV,
which was generated from an infectious clone [17]. The S27 African prototype CHIKV
strain was a gift from Dr. S. Günther (Bernhard-Nocht-Institute for Tropical Medicine,
Germany) and isolated from a patient in Tanzania in 1953.
Ethics statement. This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocols were approved by the Institutional Animal
Care and Use Committee at the Washington University School of Medicine (Assurance
Number: A3381-01) and the University of North Carolina (A3410-04). Dissections and
footpad injections were performed under anesthesia that was induced and maintained
with ketamine hydrochloride and xylazine, and all efforts were made to minimize
suffering.
Generation of chimeric SFV-CHIKV. Chimeric SFV-CHIKV virus was
generated by complementation of a double sub-genomic DNA-launched SFV replicon
“backbone” plasmid (pSFV-GFP-BB) with the structural genes of CHIKV as described
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recently for WNV [59]. The vectors and methods will be described in detail elsewhere
(TY Lin, K. Dowd, and T. Pierson, in preparation). To generate SFV-CHIKV, a DNA
fragment encoding WT or mutant CHIKV structural genes was ligated into the pSFVGFP-BB plasmid and transfected directly into HEK-293T cells using Lipofectamine
LTX. The source of CHIKV structural genes was a sub-cloning vector pCHIKV-struct:
mutations were introduced into this vector using site-directed mutagenesis and fully
sequenced. Virus was harvested at 48, 72, or 96 hours after transfection, filtered, and
stored at -80°C.
CHIKV protein. The CHIKV E2 ectodomain (residues S1-E361) and pE2-E1
(E3-E2-E1: residues S1-R64 of E3, S1-E161 of E2, and Y1-Q411 of E1 including a
(GGGS)4 polylinker between E2 and E1) of the CHIKV-LR strain were amplified from
the infectious cDNA clone using high-fidelity Phusion PCR (Thermo Scientific). The E2
ectodomain was cloned into pET21a, expressed in E. coli, and purified using an oxidative
refolding protocol followed by size-exclusion column purification using fast protein
liquid chromatography [60]. pE2-E1 was cloned into the mammalian expression vector
pHLsec (Invitrogen) with a C-terminal octa-histidine tag and modified to express the
Epstein–Barr virus EBNA-1 protein for enhanced protein expression. pE2-E1 was
expressed in serum-free HEK-293F suspension cells and purified by Ni-NTA agarose
affinity (Qiagen) and Superdex 200 gel filtration chromatography.
MAb generation. Irf7-/- mice were infected and boosted with 104 PFU of
CHIKV-LR and, depending on the experiment, given a final intravenous (i.v.) boost with
CHIKV virus-like particles [30], 25 µg of E2 protein, or 2 x 105 PFU of CHIKV-LR
three days prior to fusion with myeloma cells. Hybridomas secreting antibodies that
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reacted with CHIKV-GFP-infected BHK21-15 cells were identified by flow cytometry
and cloned by limiting dilution. MAbs were isotyped by ELISA (Pierce), adapted for
growth under serum-free conditions, and purified by protein G affinity and size exclusion
chromatography. All MAbs were screened initially with a single endpoint neutralization
assay using neat hybridoma supernatant (~10 µg/ml), which was incubated with 100 FFU
of CHIKV-LR for one hour at 37oC. MAb-virus complexes were added to BHK21-15 cell
monolayers in 6-well plates. After 90 minutes, cells were overlaid with 1% (w/v) agarose
in Modified Eagle Media (MEM) supplemented with 4% FBS. Plates were fixed with
10% formaldehyde in PBS 48 hours later, stained with crystal violet, and plaques were
counted. The VH and VL sequence of neutralizing MAbs CHK-102, CHK-152, CHK-166,
and CHK-263 were amplified from hybridoma cell RNA by a 5' RACE procedure Table
S3 in Text S1).
Chimerization of MAbs. The generation of a chimeric mouse-human CHK-9 and
CHK-152 with mouse VH and VL and human IgG1 constant regions was performed as
described previously [60]. A point mutation that abolishes FcγR and C1q binding
(N297Q) was introduced by QuikChange mutagenesis (Stratagene). Recombinant
antibodies were produced after transfection of HEK-293T cells, harvesting of
supernatant, and purification by protein A affinity chromatography.
Infection of mice. (a) Immunocompromised mice. Ifnar-/- mice were bred in
pathogen-free animal facilities of the Washington University School of Medicine and
infection experiments were performed in A-BSL3 facilities with the approval of the
Washington University Animal Studies Committee. For prophylaxis studies, MAbs were
administered by i.p. injection to 6 to 8 week-old Ifnar-/- mice one day prior to s.c.
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infection in the footpad with 10 FFU of CHIKV-LR. For therapeutic studies, 10 FFU of
CHIKV-LR was delivered 24, 48, 60, or 72 hours prior to administration of a single dose
of individual or combinations of MAbs. To monitor viral burden in vivo, mice were
g dose
-CHK
or isotype
of anti control MAb one day before

treated with a single 100

infection with 10 FFU of CHIKV-LR. Animals were sacrificed two days later for
virological analysis. After extensive perfusion with PBS, organs were harvested,
weighed,

homogenized

and

virus

was

titered

by focus-forming

assay.

(b)

Immunocompetent mice. Four to six week-old C57BL/6 mice were infected s.c. in the
footpad with 100 PFU of CHIKV SL15649 in 10 µl of PBS as described previously [17].
Some animals received 100 µg of MAb in 500 µl of PBS via an i.p. route before or after
infection. Mice were monitored daily for footpad swelling. At 10 days after infection,
mice were sacrificed and sections prepared from decalcified hind limbs [17] for
histopathological analysis. All CHIKV studies with WT mice were performed under ABSL-3 conditions and in accordance with approved protocols following University of
North Carolina guidelines.
Neutralization assays. Serial dilutions of MAb were incubated with 100 FFU of
CHIKV for one hour at 37oC. MAb-virus complexes were added to cells in 96-well
plates. After 90 minutes, cells were overlaid with 1% (w/v) methylcellulose in Modified
Eagle Media (MEM) supplemented with 4% FBS. Plates were harvested 18 to 24 hours
later, and fixed with 1% PFA in PBS. The plates were incubated sequentially with 500
ng/ml of ch-CHK-9 and horseradish peroxidase (HRP)-conjugated goat anti-human IgG
in PBS supplemented with 0.1% saponin and 0.1% BSA. CHIKV-infected foci were
visualized using TrueBlue peroxidase substrate (KPL) and quantitated on an ImmunoSpot
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5.0.37 macroanalyzer (Cellular Technologies Ltd). Non-linear regression analysis was
performed, and EC50 values were calculated after comparison to wells infected with
CHIKV in the absence of antibody.
Pre- and post-attachment neutralization assays. 96-well tissue culture plates
were coated with 100 µl of poly-L lysine and seeded with 3 x 104 Vero cells/well
overnight. For pre-attachment assays, dilutions of MAb were prepared at 4ºC in DMEM
with 2% FBS and pre-incubated with 100 FFU of CHIKV-LR for one hour at 4ºC. MAbvirus complexes were added to pre-chilled Vero cells for one hour at 4ºC. Non-adsorbed
virus was removed with three washes of DMEM and adsorbed virus was allowed to
internalize during a 37ºC incubation for 15 minutes. Cells were overlaid with 1% (w/v)
methylcellulose in MEM supplemented with 4% FBS. The post-attachment assay was
performed similarly, except that an equivalent amount of CHIKV was adsorbed first onto
Vero cells for one hour at 4ºC. After removing free virus, dilutions of MAb were added
to the virus-adsorbed cells for one hour at 4ºC. Virus was allowed to internalize and cells
were overlaid with methylcellulose as described above. Nineteen hours later, the plates
were harvested and analyzed for antigen-specific foci as described above.
Fusion inhibition assays. (a) Fusion from without assay. Virus fusion with the
plasma membrane was assessed using a fusion from without (FFWO) assay [36]. Vero
cells were seeded in 96-well plates, washed once with Binding medium (RPMI 1640,
0.2% BSA, 10 mM HEPES pH 7.4, and 20 mM NH4Cl) at 4ºC, and incubated for 15
minutes at 4ºC. CHIKV-LR (MOI of 15) was prepared in Binding medium and added to
cells for one hour at 4ºC, and then free virus was removed. Subsequently, DMEM
containing 2% FBS with or without CHIKV-specific or control MAbs (50 µg/ml) was
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added to cells for one hour at 4ºC. FFWO was induced by the addition of pre-warmed
fusion media (RPMI 1640, 0.2% BSA, 10 mM HEPES, and 30 mM succinic acid at pH
5.5) for two minutes at 37ºC. In parallel wells, control media (RPMI 1640, 0.2% BSA, 10
mM HEPES at pH 7.4) was added for 2 minutes at 37ºC to ensure that infection occurred
only through pH-dependent plasma membrane fusion. Medium was removed and cells
were incubated in DMEM supplemented with 5% FBS, 10 mM HEPES, and 20 mM
NH4Cl (pH 7.4); NH4Cl prevented secondary infection through endosomal fusion
pathways. Cells were detached 14 hours later, fixed with 1% PFA in PBS for 8 minutes,
and permeabilized with 0.1% (w/v) saponin detergent solution. Cells were incubated
sequentially with ch-CHK-9 and Alexa 647 conjugated goat anti-human IgG secondary
antibody (Invitrogen). Infection was evaluated on a FACSArray flow cytometer (BectonDickinson) and analyzed using FlowJo software. (b) Liposomal fusion assay. Pyrenelabeled CHIKV (S27 African strain) was recovered from supernatants of infected Vero76
cells cultured for 48 hours in the presence of 15 µg/ml 16-(1-pyrenyl)hexadecanoic acid
(Invitrogen) as described [37]. Fusion of pyrene-labeled CHIKV with liposomes was
monitored continuously in a Fluorolog 3-22 fluorometer (BFi Optilas), essentially as
described [37]. Pyrene-labeled CHIKV and an excess of liposomes were mixed in a final
volume of 665 µl in 5 mM HEPES, 150 mM NaCl, 0.1 mM EDTA, pH 7.4. Fusion was
triggered by the addition of 35 µl 0.1 M MES, 0.2 M acetic acid, which achieved a pH of
4.7. For the antibody inhibition experiments, pyrene-labeled CHIKV was incubated with
increasing concentrations of CHIKV-152 or isotype control IgG2a MAb (MAb 0031,
R&D systems) for 10 minutes at 37°C prior to mixing with liposomes.
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SPR. The binding of human FcγR and C1q to ch-CHK-152 and ch-CHK-152
(N297Q) was analyzed by SPR using a BIAcore 3000 biosensor (GE Healthcare Life
Sciences). MAbs were captured (~900 RU) after flowing over immobilized F(ab)’2
fragments of goat anti-human F(ab)’2 specific IgG on a CM-5 sensor chip. Binding
experiments were performed in HBS-EP buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 3
mM EDTA, and 0.005% P20 surfactant). Binding of CD16A and CD64 (as monomeric
soluble FcγR), CD32A (as dimeric soluble FcγR-aglycosylated Fc fusion), and C1q
(Sigma-Aldrich) was analyzed at a single concentration. The FcγR and C1q were injected
for 60 sec at a flow rate of 30 µl/min then allowed to dissociate over 2 minutes. Affinity
measurements of CHK-152 MAbs for pE2-E1 were performed by SPR in HBS-EP
buffer. Ch-CHK-152, ch-CHK-152 N297Q, hu-CHK-152 and mouse CHK-152 were
captured (~300 RU) after flowing over immobilized F(ab)’2 fragments of goat antihuman or anti-mouse Fc specific IgG. Purified pE2-E1 was injected at concentrations of
0, 6.25, 12.5, 25, 50, and 100 nM, at a flow rate of 30 µl/min for 120 sec, and then
allowed to dissociate over 2 minutes. Regeneration of capture surfaces was performed by
pulse injection of 10mM glycine pH 1.5. Binding curve at the zero concentration of pE2E1 was subtracted from each experimental curve as a blank. Data were analyzed using
BIAevaluation 4.1 software. Kinetic constants, ka and kd, were estimated by global fitting
analysis of the association/dissociation curves to the 1:1 Langmuir interaction model.
Escape mutant selection. CHIKV-LR (1.2 x 105 FFU) was incubated with 25
µg/ml of MAbs for one hour at 37ºC. Virus-MAb complexes were added to Vero cells
and infection proceeded for 24 hours. At each passage, half of the supernatant was mixed
(1:1) with 50 µg/ml of the selection MAb for one hour at 37ºC. These complexes were
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added to a new monolayer of Vero cells for 2 hours, and the procedure was repeated from
3 to 6 times depending on the selection MAb. Individual MAb-resistant viral plaques
were picked and virus was grown in Vero cells in the presence of 10 µg/ml of MAb for
24 hours. RNA was isolated from cells using an RNeasy kit (Qiagen) and cDNA was
made with random hexamers using the Superscript III Reverse Transcriptase kit
(Invitrogen) and amplified by PCR with primers flanking the structural genes (Table S4).
The PCR product was sequenced using ten overlapping primer sets (Table S4).
Mapping of mutations onto the CHIKV p62-E1 crystal structure. Figures
were prepared using the atomic coordinates of CHIKV pE2-E1 (RCSB accession number
3N44) using the program CCP4MG[61].
Statistical analysis. For survival analysis, Kaplan-Meier survival curves were
analyzed by the log-rank test. For growth kinetics and neutralization an unpaired T-test or
analysis of variance was used to determine significance. These analyses were assessed
using Prism software (GraphPad software). The protective effects of ch-CHK-152 versus
ch-CHK-152 N297Q in wild type C57BL/6 mice were analyzed by the Kruskal-Wallace
test with Bonferroni correction using the agricolae package of R (R Development Core
Team, 2010. Foundation for Statistical Computing, Vienna, Austria).

48

ACKNOWLEDGEMENTS
The authors greatly appreciate the generosity of our colleagues in the alphavirus
field for making reagents used in this study available and for helpful discussions. We
gratefully acknowledge M. Ferris for his assistance with some of the statistical analysis.

49

REFERENCES
1. Staples JE, Breiman RF, Powers AM (2009) Chikungunya fever: an epidemiological
review of a re-emerging infectious disease. Clin Infect Dis 49: 942-948.
2. Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT (2012) Chikungunya: a reemerging virus. Lancet 379: 662-671.
3. Schuffenecker I, Iteman I, Michault A, Murri S, Frangeul L, et al. (2006) Genome
microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS
Med 3: e263.
4. Arankalle VA, Shrivastava S, Cherian S, Gunjikar RS, Walimbe AM, et al. (2007)
Genetic divergence of Chikungunya viruses in India (1963-2006) with special
reference to the 2005-2006 explosive epidemic. J Gen Virol 88: 1967-1976.
5. Powers AM, Brault AC, Tesh RB, Weaver SC (2000) Re-emergence of Chikungunya
and O'nyong-nyong viruses: evidence for distinct geographical lineages and
distant evolutionary relationships. J Gen Virol 81: 471-479.
6. Powers AM, Logue CH (2007) Changing patterns of chikungunya virus: re-emergence
of a zoonotic arbovirus. J Gen Virol 88: 2363-2377.
7. Thiboutot MM, Kannan S, Kawalekar OU, Shedlock DJ, Khan AS, et al. (2010)
Chikungunya: a potentially emerging epidemic? PLoS Negl Trop Dis 4: e623.
8. Wang E, Volkova E, Adams AP, Forrester N, Xiao SY, et al. (2008) Chimeric
alphavirus vaccine candidates for chikungunya. Vaccine 26: 5030-5039.
9. Mukhopadhyay S, Zhang W, Gabler S, Chipman PR, Strauss EG, et al. (2006)
Mapping the structure and function of the E1 and E2 glycoproteins in
alphaviruses. Structure 14: 63-73.
10. Voss JE, Vaney MC, Duquerroy S, Vonrhein C, Girard-Blanc C, et al. (2010)
Glycoprotein organization of Chikungunya virus particles revealed by X-ray
crystallography. Nature 468: 709-712.
11. Li L, Jose J, Xiang Y, Kuhn RJ, Rossmann MG (2010) Structural changes of
envelope proteins during alphavirus fusion. Nature 468: 705-708.
12. Lescar J, Roussel A, Wien MW, Navaza J, Fuller SD, et al. (2001) The Fusion
glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for
fusogenic activation at endosomal pH. Cell 105: 137-148.
50

13. Roussel A, Lescar J, Vaney MC, Wengler G, Wengler G, et al. (2006) Structure and
interactions at the viral surface of the envelope protein E1 of Semliki Forest virus.
Structure 14: 75-86.
14. Ziegler SA, Lu L, da Rosa AP, Xiao SY, Tesh RB (2008) An animal model for
studying the pathogenesis of chikungunya virus infection. Am J Trop Med Hyg
79: 133-139.
15. Couderc T, Chretien F, Schilte C, Disson O, Brigitte M, et al. (2008) A mouse model
for Chikungunya: young age and inefficient type-I interferon signaling are risk
factors for severe disease. PLoS Pathog 4: e29.
16. Gardner J, Anraku I, Le TT, Larcher T, Major L, et al. (2010) Chikungunya virus
arthritis in adult wild-type mice. J Virol 84: 8021-8032.
17. Morrison TE, Oko L, Montgomery SA, Whitmore AC, Lotstein AR, et al. (2011) A
mouse model of chikungunya virus-induced musculoskeletal inflammatory
disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am J
Pathol 178: 32-40.
18. Rabinowitz SG, Adler WH (1973) Host defenses during primary Venezuelan equine
encephalomyelitis virus infection in mice. I. Passive transfer of protection with
immune serum and immune cells. J Immunol 110: 1345-1353.
19. Boere WA, Benaissa-Trouw BJ, Harmsen M, Kraaijeveld CA, Snippe H (1983)
Neutralizing and non-neutralizing monoclonal antibodies to the E2 glycoprotein
of Semliki Forest virus can protect mice from lethal encephalitis. J Gen Virol 64
(Pt 6): 1405-1408.
20. Mathews JH, Roehrig JT, Trent DW (1985) Role of complement and the Fc portion
of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus
infection with glycoprotein-specific monoclonal antibodies. J Virol 55: 594-600.
21. Johnson AJ, Hunt AR, Roehrig JT (1991) Synthetic peptides of Venezuelan equine
encephalomyelitis virus E2 glycoprotein. III. Identification of a protective peptide
derived from the carboxy-terminal extramembranal one-third of the protein.
Virology 185: 840-842.

51

22. Levine B, Hardwick JM, Trapp BD, Crawford TO, Bollinger RC, et al. (1991)
Antibody-mediated clearance of alphavirus infection from neurons. Science 254:
856-860.
23. Wust CJ, Nicholas JA, Fredin D, Dodd DC, Brideau RJ, et al. (1989) Monoclonal
antibodies that cross-react with the E1 glycoprotein of different alphavirus
serogroups: characterization including passive protection in vivo. Virus Res 13:
101-112.
24. Schmaljohn AL, Johnson ED, Dalrymple JM, Cole GA (1982) Non-neutralizing
monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature 297: 7072.
25. Schmaljohn AL, Kokubun KM, Cole GA (1983) Protective monoclonal antibodies
define maturational and pH-dependent antigenic changes in Sindbis virus E1
glycoprotein. Virology 130: 144-154.
26. Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, et al. (2009)
Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis 200: 516523.
27. Warter L, Lee CY, Thiagarajan R, Grandadam M, Lebecque S, et al. (2011)
Chikungunya virus envelope-specific human monoclonal antibodies with broad
neutralization potency. J Immunol 186: 3258-3264.
28. Lee CY, Kam YW, Fric J, Malleret B, Koh EG, et al. (2011) Chikungunya virus
neutralization antigens and direct cell-to-cell transmission are revealed by human
antibody-escape mutants. PLoS Pathog 7: e1002390.
29. Fric J, Bertin-Maghit S, Wang CI, Nardin A, Warter L (2013) Use of human
monoclonal antibodies to treat chikungunya virus infection. J Infect Dis 207: 319322.
30. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, et al. (2010) A virus-like
particle vaccine for epidemic Chikungunya virus protects nonhuman primates
against infection. Nat Med 16: 334-338.
31. Schilte C, Buckwalter MR, Laird ME, Diamond MS, Schwartz O, et al. (2012)
Cutting edge: independent roles for IRF-3 and IRF-7 in hematopoietic and

52

nonhematopoietic cells during host response to Chikungunya infection. J
Immunol 188: 2967-2971.
32. Zinkernagel RM, LaMarre A, Ciurea A, Hunziker L, Ochsenbein AF, et al. (2001)
Neutralizing antiviral antibody responses. Adv Immunol 79: 1-53.
33. Pierson TC, Diamond MS (2008) Molecular mechanisms of antibody-mediated
neutralization of flavivirus infection. Exp Rev Mol Med 10: e12.
34. Nybakken G, Oliphant T, Johnson S, Burke S, Diamond MS, et al. (2005) Structural
basis for neutralization of a therapeutic antibody against West Nile virus. Nature
437: 764-769.
35. Crill WD, Roehrig JT (2001) Monoclonal antibodies that bind to domain III of
dengue virus E glycoprotein are the most efficient blockers of virus adsorption to
Vero cells. J Virol 75: 7769-7773.
36. Edwards J, Brown DT (1986) Sindbis virus-mediated cell fusion from without is a
two-step event. J Gen Virol 67 ( Pt 2): 377-380.
37. Smit JM, Bittman R, Wilschut J (1999) Low-pH-dependent fusion of Sindbis virus
with receptor-free cholesterol- and sphingolipid-containing liposomes. J Virol 73:
8476-8484.
38. Smit JM, Waarts BL, Bittman R, Wilschut J (2003) Liposomes as target membranes
in the study of virus receptor interaction and membrane fusion. Methods Enzymol
372: 374-392.
39. Tao MH, Morrison SL (1989) Studies of aglycosylated chimeric mouse-human IgG.
Role of carbohydrate in the structure and effector functions mediated by the
human IgG constant region. J Immunol 143: 2595-2601.
40. Labadie K, Larcher T, Joubert C, Mannioui A, Delache B, et al. (2010) Chikungunya
disease in nonhuman primates involves long-term viral persistence in
macrophages. J Clin Invest 120: 894-906.
41. Coffey LL, Vignuzzi M (2011) Host alternation of chikungunya virus increases
fitness while restricting population diversity and adaptability to novel selective
pressures. J Virol 85: 1025-1035.

53

42. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, et al. (2007) The
stoichiometry of antibody-mediated neutralization and enhancement of West Nile
virus infection. Cell Host and Microbe 1: 135-145.
43. Boere WA, Benaissa-Trouw BJ, Harmsen T, Erich T, Kraaijeveld CA, et al. (1985)
Mechanisms of monoclonal antibody-mediated protection against virulent Semliki
Forest virus. J Virol 54: 546-551.
44. Martin V, Perales C, Davila M, Domingo E (2006) Viral fitness can influence the
repertoire of virus variants selected by antibodies. J Mol Biol 362: 44-54.
45. Sun S, Xiang Y, Wataru A, Holdaway HA, Pal P, et al. (2013) Structural analyses at
pseudo atomic resolution of Chikungunya virus antibody neutralization
mechanisms. eLife: In press.
46. Agapov EV, Razumov IA, Frolov IV, Kolykhalov AA, Netesov SV, et al. (1994)
Localization

of

four

antigenic

sites

involved

in

Venezuelan

equine

encephalomyelitis virus protection. Arch Virol 139: 173-181.
47. Pence DF, Davis NL, Johnston RE (1990) Antigenic and genetic characterization of
Sindbis virus monoclonal antibody escape mutants which define a pathogenesis
domain on glycoprotein E2. Virology 175: 41-49.
48. Mendoza QP, Stanley J, Griffin DE (1988) Monoclonal antibodies to the E1 and E2
glycoproteins of Sindbis virus: definition of epitopes and efficiency of protection
from fatal encephalitis. J Gen Virol 69 ( Pt 12): 3015-3022.
49. Stanley J, Cooper SJ, Griffin DE (1986) Monoclonal antibody cure and prophylaxis
of lethal Sindbis virus encephalitis in mice. J Virol 58: 107-115.
50. Vrati S, Fernon CA, Dalgarno L, Weir RC (1988) Location of a major antigenic site
involved in Ross River virus neutralization. Virology 162: 346-353.
51. Strauss EG, Stec DS, Schmaljohn AL, Strauss JH (1991) Identification of
antigenically important domains in the glycoproteins of Sindbis virus by analysis
of antibody escape variants. J Virol 65: 4654-4664.
52. Davis NL, Pence DF, Meyer WJ, Schmaljohn AL, Johnston RE (1987) Alternative
forms of a strain-specific neutralizing antigenic site on the Sindbis virus E2
glycoprotein. Virology 161: 101-108.

54

53. Roehrig JT, Day JW, Kinney RM (1982) Antigenic analysis of the surface
glycoproteins of a Venezuelan equine encephalomyelitis virus (TC-83) using
monoclonal antibodies. Virology 118: 269-278.
54. Roehrig JT, Mathews JH (1985) The neutralization site on the E2 glycoprotein of
Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple
conformationally stable epitopes. Virology 142: 347-356.
55. Qiu X, Audet J, Wong G, Pillet S, Bello A, et al. (2012) Successful treatment of ebola
virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med
4: 138ra181.
56. Prabakaran M, Prabhu N, He F, Hongliang Q, Ho HT, et al. (2009) Combination
therapy using chimeric monoclonal antibodies protects mice from lethal H5N1
infection and prevents formation of escape mutants. PLoS One 4: e5672.
57. Goudsmit J, Marissen WE, Weldon WC, Niezgoda M, Hanlon CA, et al. (2006)
Comparison of an anti-rabies human monoclonal antibody combination with
human polyclonal anti-rabies immune globulin. J Infect Dis 193: 796-801.
58. Tsetsarkin K, Higgs S, McGee CE, De Lamballerie X, Charrel RN, et al. (2006)
Infectious clones of Chikungunya virus (La Reunion isolate) for vector
competence studies. Vector Borne Zoonotic Dis 6: 325-337.
59. Lin TY, Dowd KA, Manhart CJ, Nelson S, Whitehead SS, et al. (2012) A novel
approach for the rapid mutagenesis and directed evolution of the structural genes
of west nile virus. J Virol 86: 3501-3512.
60. Oliphant T, Engle M, Nybakken G, Doane C, Johnson S, et al. (2005) Development
of a humanized monoclonal antibody with therapeutic potential against West Nile
virus. Nature Medicine 11: 522-530.
61. Potterton L, McNicholas S, Krissinel E, Gruber J, Cowtan K, et al. (2004)
Developments in the CCP4 molecular-graphics project. Acta Crystallogr D Biol
Crystallogr 60: 2288-2294.

55

FIGURE LEGENDS
Figure 1. Profile of neutralizing MAbs against CHIKV. A. Examples of MAb
neutralization as judged by a reduction in the number of FFU using the Biospot
Macroanalyzer. Rows 2 to 12 going across represent decreasing (3-fold) concentrations
of CHK-152 or the negative control DENV1-E98 MAb. Column 1 shows infection in the
absence of MAb. B. Increasing concentrations of CHK-95, CHK-102, CHK-166, CHK187, or CHK-263 were mixed with 100 to 150 FFU of CHIKV-LR for one hour at 37°C
and Vero cells were infected. Neutralization was determined by FFU assay. C-D. CHK152 (C) or CHK-9 (D) was mixed with CHIKV-LR (East, Central and South African
genotype), CHIKV-RSUI (Asian genotype), or CHIKV IbH35 (West African genotype)
for one hour at 37°C and Vero or NIH 3T3 cells were infected as indicated.
Neutralization was determined by FFU assay. Data in this Figure is pooled from three
independent experiments performed in duplicate or triplicate. All error bars represent the
standard deviations.
Figure 2. Efficacy of anti-CHIKV MAb prophylaxis. A. Six to eight week-old
Ifnar-/- C57BL/6 mice were passively transferred 100 µg of the indicated MAbs via an
i.p. injection one day before infection with 10 FFU of CHIKV-LR via a s.c. route. The
percentage and number of surviving mice were as follows: DENV1-E98 (0%, 0 of 9),
CHK-88 (62.5%; 5 of 8), CHK-95 (12.5%; 1 of 8), CHK-98 (28.6%; 2 of 7), CHK-102
(100%; 8 of 8), CHK-124 (75%; 6 of 8), CHK-151 (87.5%; 7 of 8), CHK-152 (100%; 8
of 8), CHK-155 (85.7%; 6 of 7), CHK-165 (28.6%; 2 of 7), CHK-166 (100%; 8 of 8),
CHK-175 (75%; 6 of 8), CHK-187 (50%; 4 of 8), CHK-263 (100%; 8 of 8), or CHK-266
(0%; 0 of 8). MAbs italicized in red in the Figure provided 100% protection. B. Ifnar-/mice were passively transferred 10 µg of MAb via an i.p. injection one day before
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infection with 10 FFU of CHIKV-LR via a s.c. route. The percentage and number of
surviving mice were as follows: DENV1-E98 (0%; 0 of 7), CHK-102 (12.5%; 1 of 8),
CHK-152 (83%; 10 of 12), CHK-166 (0%; 0 of 12), or CHK-263 (73%; 8 of 11). For (A)
and (B) the survival curves were constructed from data of at least two independent
experiments. All anti-CHK MAbs provided statistically significant protection in the
percentage of surviving animals or mean survival time compared to the control DENV1E98 MAb (P < 0.05). C-G. Viral burden in MAb-treated Ifnar-/- mice. Animals were
passively transferred 100 µg of the indicated MAbs (CHK-102, CHK-152, CHK-166,
CHK-263, or isotype control DENV1-E98) via an i.p. injection one day before infection
with 10 FFU of CHIKV-LR via a s.c. route. Two days later, viremia (C) and tissues (D,
spleen; E, liver; F, muscle; and G, brain) were harvested and infectious virus was titrated
by focus-forming assay. Results are pooled from two independent experiments (n = 4
mice per group). The dashed line indicates the limit of detection of the assay and the solid
bar indicates the median values. All viral burden results with CHK-102, CHK-152, CHK166, and CHK-263 were statistically different (P < 0.02) from those obtained with
DENV1-E98, as analyzed by the Mann-Whitney test. H. Four week-old female WT
C57BL/6 mice were sham-treated or administered 100 µg of CHK-102 or CHK-152 via
an i.p. route. 24 hours later, mice were infected with 100 PFU of CHIKV-SL 15649 and
at day 10, virus-induced pathology in the foot and ankle joint was assessed. (Outer left)
Sham-infected, (middle left) CHIKV infected and sham-treated, (middle right) CHIKVinfected and CHK-102 treated, and (outer right) CHIKV infected and CHK-152 treated.
Shown are representative images after hematoxylin and eosin staining from at least 3
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mice per group at 100x magnification. Yellow and green arrows indicate regions of
inflammation or normal joints, respectively.
Figure 3. Mechanism of neutralization by CHIKV MAbs. A. Pre- and postattachment inhibition assays. Vero cells were pre-chilled to 4ºC and 100 FFU of CHIKVLR was added to each well for one hour. After extensive washing at 4oC, the indicated
MAbs were added for one hour at 4ºC, and then the FRNT protocol was completed (black
lines, Post). In comparison, a standard pre-incubation FRNT with all steps performed at
4ºC is shown for reference. Virus and MAb are incubated together for one hour at 4oC,
prior to addition to cells (red lines, Pre). Data shown are representative of three
experiments performed in duplicate with error bars representing standard deviation. B-C.
FFWO assay. CHIKV was incubated with Vero cells at 4oC to allow virus attachment.
Free virus was removed after washing and 50 µg/ml of the indicated MAbs (including
DENV1-E98, a negative control MAb) were added at 4oC. Viral fusion at the plasma
membrane was induced after a brief exposure to a low pH buffer. After pH normalization,
cells were cultured for 14 hours in the presence of NH4Cl to inhibit infection through the
endosomal pathway. Cells were analyzed for infection by staining with an anti-E2 MAb.
Representative histograms are shown (B) and the data was pooled from four independent
experiments for statistical analysis (C). For simplicity of display, not all of the MAbs
included in the summary graph are shown by flow cytometry analysis. Asterisks indicate
values that are statistically different (P < 0.05) from the control MAb. Error bars
represent standard deviations. Note low pH-triggered viral fusion at the plasma
membrane is an inefficient process with only 10 to 20% of cells becoming infected even
when a high MOI was used. D-E. Viral membrane fusion with liposomes. Fusion of
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pyrene-labeled CHIKV was measured at pH 4.7 (37°C) using liposomes consisting of
phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, and cholesterol in a
molar ratio of (1/1/1/1.5), as described in the Methods. (D) Curve a, no MAb; curve b,
0.1 nM CHK-152; curve c, 1 nM CHK-152; curve d, 10 nM CHK-152. (E) Extent of
fusion (average value between 50 to 60 seconds post acidification) at increasing
concentrations of MAb. Black bars, CHK-152; white bar, isotype control (MAb 0031,
only included at 10 nM concentration). All fusion measurements were performed at least
three independent times.
Figure 4. The effector functions of CHK-152 contribute to protection in vivo.
A. Comparison of binding of ch-CHK-152 and agylocsyl ch-CHK-152 N297Q to pE2E1, as measured by surface plasmon resonance. A single representative sensogram is
shown for each MAb. The experimental curves (colored lines) were fit using a 1:1
Langmuir analysis (dashed lines), after double referencing, to determine the kinetic
parameters presented in the Table immediately below. B. Comparison of neutralizing
activity of murine CHK-152, ch-CHK-152, and ch-CHK-152 N297Q, as measured by
FRNT on Vero cells. C. Comparison of binding of ch-CHK-152 and ch-CHK-152
N297Q to FcγR (CD16A, 500 nM; CD32A, 100 nM; and CD64, 100 nM) or C1q (50
nM), as measured by surface plasmon resonance. D. Comparison of pre-exposure
protective activity of ch-CHK-152 and ch-CHK-152 N297Q. Ifnar-/- mice were
administered via an i.p. injection 10 µg of ch-CHK-152 and ch-CHK-152 N297Q one day
before infection with 10 FFU of CHIKV-LR via a s.c. route. Mice were monitored for
survival for 21 days after infection. The survival curves were constructed from data of at
least two independent experiments and the number of animals for each antibody ranged
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from 8 to 10 per group. ch-CHK-152 provided statistically greater protection than chCHK-152 N297Q (P < 0.05). E. Five week-old WT C57BL/6 mice were infected with
100 PFU of CHIKV in the left rear footpad and either sham-treated, or treated with 100,
50, or 25 µg of ch-CHK-152 (left panel) or ch-CHK-152 N297Q (right panel) at 18 hours
post infection. Mice were scored daily for virus-induced footpad swelling, where a score
of 0 = no swelling, 1 = mild swelling where the top of the foot is slightly raised, 2 =
moderate swelling with the entire top of foot raised, and 3 = severe swelling involving
both the top and bottom of the foot. Scores are the mean values for 7 to 8 mice per
treatment group and are representative of three independent experiments. Ch-CHK-152
mediated protection was significantly greater than ch-CHK-152 N297Q on days 7, 8, and
9 post infection for the 100 µg antibody dose, and at day 7 post infection for the 50 µg
dose, as determined by the Kruskal-Wallace test with Bonferroni correction (P < 0.05).
No statistically significant differences between ch-CHK-152 and ch-CHK-152 N297Q
were observed with the 25 µg dose. Of note, we observed a reproducible decrease in
clinical score on day 5 in many animals. This reflects the biphasic pattern of swelling:
during the first 3 to 4 days, swelling is due to edema, whereas after day 5, it is due to
inflammatory cell infiltration into the foot and ankle.
Figure 5. Therapeutic efficacy of anti-CHIKV MAbs. A. Ifnar-/- mice were
passively transferred via an i.p. injection 100 µg of DENV1-E98, CHK-102, CHK-152,
CHK-166, or CHK-263 or 50 µg each of CHK-102 + CHK-152, CHK-166 + CHK-152,
CHK-263 + CHK-152, or CHK-102 + CHK-263 at 24 hours after CHIKV infection. B.
Five week-old WT C57BL/6 mice were infected with 100 PFU of CHIKV in the footpad
and either sham-treated, or treated with 100 or 50 µg of CHK-152 at 18 hours post

60

infection. Virus induced pathology in the foot and ankle joint was assessed by
histopathological analysis at day 10 post-infection. (Left) CHIKV-infected, sham-treated,
(middle) CHIKV-infected, CHK-152 (100 µg) treated at + 18 hours, and (right) CHIKVinfected, CHK-152 (50 µg) treated at + 18 hours. Shown are representative images after
hematoxylin and eosin staining from 3 mice per group at 100x magnification. Yellow and
green arrows indicate regions of inflammation or normal joints, respectively. C. Ifnar-/mice were passively transferred via an i.p. injection 200 µg of DENV1-E98 or 100 µg
each of CHK-102 + CHK-152, CHK-166 + CHK-152, or CHK-263 + CHK-152 at 48
hours after CHIKV infection. D. Ifnar-/- mice were passively transferred via an i.p.
injection 500 µg of DENV1-E98 or 250 µg each of CHK-102 + CHK-152 or CHK-166 +
CHK-152 at 60 hours after CHIKV infection. For A, C, and D the survival curves were
constructed from data of at least two independent experiments. The number of animals
for each antibody ranged from 8 to 10 per group, with the exception of CHK-102 + CHK263, which was performed with 7 mice only. Statistically significant differences in
protection compared to DENV1-E98 are described in the text.
Figure 6. Characterization and mapping of neutralization escape mutants. AD. FRNT assay with bulk virus obtained after three to six passages under selection of (A)
CHK-102, (B) CHK-152, (C) CHK-166, or (D) CHK-263 on Vero cells. Bulk virus also
was tested for infectivity in the presence of the non-selecting MAbs. Results are
representative of two to three independent experiments performed in triplicate. E-H.
Confirmation of resistant phenotype with SFV-CHIKV-GFP containing the indicated
single engineered point mutations. Serial dilutions of MAb were incubated with chimeric
SFV-CHIKV virus (WT or mutant stocks) for one hour at room temperature. MAb-virus
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complexes were added to Vero cells plated in 96-well plates and incubated at 37°C. After
8 hours cells were trypsinized, fixed, and the number of GFP-positive, infected cells was
assessed by flow cytometry. Curves are representative of 2 to 3 independent experiments.
I. Epitope mapping of anti-CHIKV MAbs on the crystal structure of the mature envelope
glycoprotein complex (PDB code 3N44). (Left) The domains on E2 (cyan) and E1 (gold)
are indicated, and the fusion loop on E1 (E1 FL) is delineated. Amino acid residues of
neutralizing MAbs were determined by escape selection, sequencing, and reverse genetic
confirmation. CHK-102 and CHK-263 recognize the B domain on E2, CHK-152
recognizes a residue on the wings of the A domain on E2, and CHK-166 recognizes an
amino acid in domain II of E1 proximal to the conserved fusion loop. (Right) The mature
envelope glycoprotein docked onto the trimer conformation (PDB code 2XFB) that is
present on the virion. E3, E2, and E1 and the escape residues are colored as in the left
panel. Neutralization escape residues are readily accessible on the top of the trimer, distal
to the viral membrane.
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Table 1. Inhibitory activity of neutralizing anti-CHIKV MAbs
MAb

CHK-9

CHK-11

CHIKV-

CHIKV-

CHIKV-

CHIKV-

CHIKV-

CHIKV-

CHIKV-

LR

LR

LR

RSU1

RSU1

IbH35

IbH35

EC50

EC90

EC50

EC50

EC90

EC50

EC90

ng/ml

ng/ml

ng/ml

ng/ml

ng/ml

ng/ml

ng/ml

(CI)

(CI)

(CI)

(CI)

(CI)

(CI)

(CI)

Vero

Vero

3T3

Vero

Vero

Vero

Vero

36 (31-

882 (612-

43)

1271)

>10,000

68 (54-87)

1356
(1049-

>10,000

CHK-65
CHK-77
CHK-88
CHK-95
CHK-96

430 (304-

20)

607)

7 (6-9)

CHK-105

25 (15-43)

5 (4-6)

91 (53-

56)

(407-817)

155)

5 (3-6)

4 (3-5)

40 (33-

155 (130-

422 (230776)
156 (90271)

(36307846)
351 (227-

17)

543)

19 (16-

CHK-112
11 (9-13)

4 (4-6)

2 (2-3)

6 (4-10)

6 (5-8)

>10,000

13982)
5337

1156
(7731728)
235 (162339)
101 (66-

17 (14-20)

12 (7-21)

8457
(5115-

14 (11-

23)

CHK-124

1047)

308)

8 (7-11)

576

183)

CHK-102

587 (330-

215 (150-

32 (17-61)

48 (41-

50)

CHK-98

(36915932)

16 (14-

(2636 5229)

4680

1753)

CHK-48

3712
37 (27-51)

95 (65 139)

394 (220-

21 (16-

706)

27)

>10,000

220 (121399)
265 (164431)
368 (250543)
190 (106343)
411 (246686)

1141 (5702284)

7 (5-9)

4 (3-5)

27 (22-32)

2 (2-3)

2 (1-3)

5 (4-7)

19 (14-26)

150)

11 (9-14)

2022
(9504304)

103 (80131)

(532-

6 (5-7)

927 (5631528)

11 (9-13)

2116
12 (8-19)

8 (6-11)

(1072-

4 (3-5)

4174)
10 (5-22)

3 (2-4)
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>10,000

359 (193669)
147 (80271)
444 (291677)
211 (104431)
176 (76404)

(21269466)

3261)
94 (59-

2469)

4486
>10,000

1318
30 (17-53)

1478 (885-

228 (129-

3 (2-3)

7923
(449413968)
104 (68161)

645 (433960)

115 (76176)
96 (55-167)

156)

CHK-140
CHK-142
CHK-143

9 (8-11)

9 (7-11)

34 (2351)

CHK-151

219 (137348)
369 (238572)

>10,000

402)
56 (32-98)

8 (6-11)

32 (21-48)

7 (5-10)

277 (761010)

6883
(3467-

>10,000

>10,000

13665)

CHK-152
CHK-155
CHK-164

2 (2-2)
5 (5-7)

10 (9-12)
110 (73166)

3523
(2904-

>10,000

4274)

CHK-165

(6275-

154 (116205)

CHK-175
CHK-176

6 (5-8)
806 (616
- 1055)

CHK-180

140 (104
-186)

CHK-187
CHK-189

11 (9-12)

CHK-262

>10,000

261(154440)

7 (6-8)

4 (4-5)

4395

1637

(3045-

(1182-

6342)

2265)

>10,000

(111-

8604
(445916604)
423 (285626)
>10,000
7615
(390714843)
524 (355772)

202 (98-

12 (7-23)

108 (66177)
3094 (72813143)

5784
>10,000

(2785-

>10,000

12015)
15 (11-22)
93 (61142)

1 (1-2)

6 (5-8)

2 (2-3)

52 (32-86)

2366
>10,000

(1582-

>10,000

3538)

>10,000

>10,000

418)

40 (30-52)

>10,000

3 (3-4)

>10,000

>10,000

168 (74384)

17 (8-34)

(2119-

49 (38-63)

7 (6-8)

951 (5891538)
4622

(2488-

(3376-

5623)

6328)

2 (2-4)

4 (3-5)

197)

343 (199593)
>10,000

(1465-
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140 (97203)

(12345379)

4 (3-5)

>10,000

79 (58-108)

4570)

3740

136 (93-

82 (59-114)

2588

4934
>10,000

(1195-

2576

3959)

5 (3-10)

3974
>10,000

2175

7451)

5 (5-7)

(1332-

83 (55-125)

2972)

6181)

CHK-263

1668)

4 (3-5)

8965)

5897)

(3938-

731 (321-

5 (4-6)

1817

4325
(3172-

6 (5-9)

3 (2-3)

15070)

CHK-166

1508)

3456

1 (1-2)

9725

721 (345-

5 (4-7)

662 (2951489)
>10,000

1597 (8023180)
186 (91383)

3809
>10,000

(1856-

>10,000

7816)
3306
>10,000

(2049-

>10,000

5336)
48 (32-73)

2 (2-2)

51 (36-74)

CHK-264

18 (1323)

CHK-265
CHK-266

8 (7-9)

1019
>10,000

207 (148289)

18 (1423)

CHK-268

CHK-269

>10,000

CHK-270

(628-

1540)

21)

(1093-

>10,000

3 (3-5)

9 (7-11)

1799)

30)

14 (10-

5 (4-6)

1063

934 (567-

178)

6 (4-8)

143 (88234)

>10,000

2059)

24 (19-

136 (104-

(430-

1500

2913)

CHK-267

9 (7-14)

11 (7-16)

2419)

2187
(1642-

6 (4-10)

5962

452 (262780)

5 (4-6)

1330 (8142173)

14 (6-34)

1212
10 (7-14)

22 (17-29)

(641-

(209916932)

10 (8-13)

2289)

201 (103389)

>10,000

3694 (46829151)

468 (278789)
3834

>10,000

32 (18-57)

50 (33-76)

>10,000

47 (33-69)

(16179090)

9302
(3777-

N.D.

14 (10-18)

22912)

669 (3401317)

8 (6-11)

748 (3631537)

Neutralizing activity was determined by FRNT on Vero or NIH 3T3 cells with increasing
concentrations of purified MAbs and 100 FFU of the indicated CHIKV strains
corresponding to different genotypes (CHIKV-LR, East, Central, and South African;
CHIKV-RSUI, Asian and, IbH35, West African). The data were derived from three
independent experiments performed in duplicate or triplicate. The inhibitory
concentrations of MAb that reduced infected foci by 50% (EC50) and 90% (EC90) were
calculated by nonlinear regression analysis and are expressed as ng/ml of antibody. In
parenthesis, immediately below the EC50 and EC90 values, are confidence intervals (CI).
Bold red indicates that the EC50 or EC90 value was greater than the highest
concentration (10,000 ng/ml) of MAb used. Bold blue indicates an EC50 or EC90 value
of less than 10 ng/ml, which reflects a highly neutralizing MAb for a given cell type or

65

virus strain. N.D. indicates not determined. Of note, NIH 3T3 cells are less permissive
than Vero cells (1 FFU on NIH 3T3 cells = 35 FFU on Vero cells).
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Table 2. In vitro selection of viruses resistant to MAb neutralization

a

MAb

Mutationa

# of plaque picks

CHK-102

E2: L210P

6 of 8

CHK-102

E2: G209E

2 of 8

CHK-152

E2: D59N

9 of 9

CHK-152

b

E2: A89E

2 of 9

CHK-166

E1: K61T

14 of 14

CHK-263

E2: K215E

3 of 4

CHK-263

E2: G209E

1 of 4

In vitro selection for neutralization escape variants was performed by passaging

CHIKV-LR in the presence of 25 µg/ml of the indicated MAbs. Resistant virus was
isolated at passage 3 (CHK-102, CHK-152, and CHK-263) or passage 6 (CHK-166),
plaque purified, and sequenced.
b

The A89E mutant was identified after sequencing of CHK-152 escape mutants in cell

culture, but was determined to be insignificant for CHK-152 neutralization by reverse
genetic analysis (see Fig 6F).
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Table 3. In vivo selection of viruses resistant to MAb neutralization
EC50 (ng/ml)
MAb

Mutationa

Condition
(Parentmutant)

CHK-102

- 24 h, 10 µg

11 >10,000

E2: L210P

CHK-102

+ 24 h, 100 µg

11 >10,000

E2: G209E

CHK-152

-24 h, 10 µg

2 10,000

E2: N231D
E2: K233E
CHK-152

-24 h, 10 µg

2 3,000

E2: K233E

CHK-152

+ 24 h, 100 µg

2 >10,000

E2: D59N

CHK-152

+ 24 h, 100 µg

2 >10,000

E2: K233T

CHK-166

+ 24 h, 100 µg

170>10,000

E1: G64S

CHK-263

+ 24 h, 100 µg

5 >10,000

E2: G209E

CHK-166 +

CHK-166: 170 540
+48 h, 250 µg

CHK-152

a

E2: N332I
CHK-152: 2 2.6

In vivo selection for resistant virus was performed by administering the indicated

individual or combinations of MAbs before (-24 hours) or after (+ 24 or 48 hours)
CHIKV-LR infection. Resistant virus was isolated directly from tissues (leg and brain),
and cDNA was prepared by reverse transcription and sequenced. The change in
neutralizing activity of the bulk virus recovered from tissue is highlighted by the
differences in EC50 values.
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SUPPORTING INFORMATION
Figure S1. Screening of hybridoma supernatants for binding to CHIKV-infected
cells.
Figure S2. Binding kinetics of CHK-MAbs to pE2-E1.
Figure S3. Pre- and post-attachment neutralization assays.
Figure S4. Construction and efficacy of humanized CHK-152.
Figure S5. Interaction of neutralizing MAbs.
Figure S6. Selection of escape E1-G64S escape mutant in vivo against CHK- 166.
Figure S7. Confirmation of neutralization escape mutants selected in vivo.
Figure S8. Relative resistance of CHIKV recovered from mice after treatment with
combination MAb therapy.
Table S1. List of anti-CHIKV MAbs.
Table S2. Cross-neutralization of infection by wild type and mutant SFV-CHIKV
infection with anti-CHIKV MAbs.
Table S3. List of VH and VL sequences of CHK-102, CHK-152, CHK-166, and CHK263 mouse MAbs.
Table S4. Primers used for sequencing and amplifying the structural genes of
CHIKV-LR 2006-OPY1.
Text S1. Supplemental Methods.
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SUPPORTING INFORMATION
Figure S1. Screening of hybridoma supernatants for binding to CHIKVinfected cells. Hybridoma supernatants were incubated with CHIKV-GFP infected
BHK21 cells and tested for immunoreactivity by flow cytometry. Shown are examples of
a negative control MAb (DENV3-E2), three ‘hits’ (later named as CHK-102, CHK-117,
and CHK-130), and a negative supernatant (5E3). The y-axis shows GFP staining
associated with the reporter gene that is translated from the subgenomic promoter of
CHIKV, and the x-axis shows staining of the tested mouse MAb. Double-positive cells
were considered ‘hits’ in the screen. The result is representative of many different MAbs
performed in the original screen.
Figure S2. Binding kinetics of CHK-MAbs to pE2-E1. Binding curves and
kinetic parameters of pE2-E1 binding to mouse CHK-102, CHK-152, CHK-166, and
CHK-263 MAbs. A single representative sensogram is shown for each MAb. The
experimental curves (colored lines) were fit using a 1:1 Langmuir analysis (dashed lines),
after double referencing, to determine the kinetic parameters presented immediately
below.
Figure S3. Pre- and post-attachment neutralization assays. Vero cells were
pre-chilled to 4ºC and 100 FFU of CHIKV-LR was added to each well for one hour at 4
ºC. After extensive washing at 4oC, the indicated MAbs (CHK-48, CHK-65, CHK-95,
CHK-112, CHK-124, CHK-142, CHK-155, CHK-175, CHK-84 and DENV1-E98) were
added for one hour at 4ºC, and then the FRNT protocol was completed (black lines,
Post). In comparison, a standard pre-incubation FRNT with all steps performed at 4ºC is
shown for reference. Virus and MAb are incubated together for one hour at 4oC, prior to
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addition to cells (red lines, Pre). Data shown are representative of three experiments
performed in duplicate with error bars representing standard deviation.
Figure S4. Construction and efficacy of humanized CHK-152. We amplified
the cDNA encoding the heavy (VH) and light (VL) variable domains from the hybridoma
cellular RNA and grafted the complementarity determining regions onto the human VH118 and human Vκ-L6 backbones. The resulting humanized VH and VL were combined
with human γ1 and κ constant regions, fused to an IgG signal sequence, expressed in
293T cells and purified (data not shown). A. Binding curves and kinetic parameters of
pE2-E1 binding to mouse CHK-152 and hu-CHK-152. A single representative sensogram
is shown for each MAb. The experimental curves (colored lines) were fit using a 1:1
Langmuir analysis (dashed lines), after double referencing, to determine the kinetic
parameters presented in the Table immediately below. B. Neutralization studies with
mouse CHK-152 and hu-CHK-152. Neutralizing activity was determined by FRNT assay
on Vero cells. Samples were performed in duplicate and the experiment is one
representative of three. C. Pre-exposure protective activity of hu-CHK-152. Ifnar-/- mice
were passively transferred via an i.p. injection 10 or 100 µg of mouse hu-CHK-152 one
day before CHIKV infection. Mice were monitored for survival for 21 days after
infection. The survival curves were constructed from data of at least two independent
experiments and the number of animals for each antibody ranged from 8 to 10 per group.
Figure S5. Interaction of neutralizing MAbs. A. Virion capture ELISA and
competition of MAb binding. 96-well plates were coated with 5 µg/ml of CHK-65 MAb.
Plates were washed, blocked and 3 x 106 FFU of CHIKV 181-25 was captured.
Subsequently, plates were incubated with the indicated anti-CHK mouse MAbs (CHK-
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102, CHK-152, CHK-166, or CHK-263) or controls (no MAb, PBS; irrelevant MAb,
WNV E28) for one hour. After washing, plates were incubated sequentially with 125
ng/ml hu-CHK-152 and biotin-labeled goat anti-human secondary antibody. After
washing and incubation with HRP-conjugated streptavidin, plates were developed and
emission (450 nm) was read using an iMark microplate reader (Bio-Rad). Results are
representative of three independent experiments, each performed in triplicate. B.
Neutralizing activity of MAb combinations. Increasing concentrations of individual
MAbs (CHK-102, CHK-152, CHK-166, and CHK-263) or combinations of MAbs (CHK102 + CHK-152, CHK 102 + CHK-263, CHK-152 + CHK-166, or CHK-152 + CHK263) were mixed with 100 FFU of CHIKV-LR for one 1 hour at 37°C and Vero cells
were infected. Neutralization was determined by FFU assay. Data is representative of
three independent experiments performed in duplicate.
Figure S6. Selection of escape E1-G64S escape mutant in vivo against CHK166. Ifnar-/- mice were infected with CHIKV and 24 hours later given a single 100 µg
dose of CHK-166 therapy. Virus was recovered from the contralateral leg and brain from
one moribund mice and the structural genes were sequenced. All 2 of 2 viral isolates
recovered showed a single point G64S mutation in the E1 gene. This isolate was tested
subsequently for neutralization by CHK-102 (EC50 of 161 ng/ml), CHK-152 (EC50 of 2
ng/ml), CHK-166 (EC50 > 10,000 ng/ml) and CHK-263 (25 ng/ml). Data is the average
of two independent experiments performed in triplicate.
Figure S7. Confirmation of neutralization escape mutants selected in vivo.
Confirmation of resistant phenotype selected with CHK-152 in vivo using SFV-CHIKVGFP containing the indicated single engineered point mutations. Serial dilutions of CHK-
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152, CHK-102, and CHK-263 were incubated with chimeric SFV-CHIKV virus (WT or
mutant stocks) for one hour at room temperature. MAb-virus complexes were added to
Vero cells plated in 96-well plates and incubated at 37°C. After 8 hours cells were
trypsinized, fixed, and the number of GFP-positive, infected cells was assessed by flow
cytometry. Curves are representative of 2 independent experiments.
Figure S8. Relative resistance of CHIKV recovered from mice after
treatment with combination MAb therapy. Ifnar-/- mice were infected with CHIKV
and 48 hours later given a single dose of combination MAb (CHK-102 + CHK-152 or
CHK-166 + CHK-152) therapy. Virus was recovered from the contralateral leg and/or
brain from the few moribund mice and the structural genes were sequenced. Two viral
isolates showed differences in neutralization patterns that corresponded to amino acid
substitutions (see Table 2). Neutralization analysis of these viruses recovered from
animals treated with (left) CHK-102 and CHK-152 or (right) CHK-166 and CHK-152
and tested against the respective MAbs. A comparison with the parent virus is shown.
The curves are representative of two independent experiments performed in triplicate,
and error bars indicate standard deviations.
Table S1. List of anti-CHIKV MAbs. All MAbs listed were cloned successfully
by limiting dilution. Isotypes were assigned based on a commercial assay. MAbs CHK-1
to CHK-51 were produced from mice receiving a final boost with CHIKV VLP; MAbs
CHK-52 to CHK-145 were produced from mice receiving a final boost with recombinant
E2 protein; and MAbs CHK-146 to CHK-270 were produced from mice receiving a final
boost with either recombinant E2 protein or infectious CHIKV-LR. Binding to soluble E2
or pE2-E1 expressed in bacteria or mammalian cells was determined by ELISA. N.D.
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indicates not determined. Yes, reflects binding that yielded an O.D. value of > 1.1; Weak,
indicates binding with an O.D. value of > 0.8 and < 1.1; Background binding (irrelevant
MAb control) had an O.D. value of 0.2.
Table S2. Cross-neutralization of infection by wild type and mutant SFVCHIKV infection with anti-CHIKV MAbs. CHIKV escape variants were selected in
the presence of the indicated neutralizing MAbs. After sequencing of escape variants, the
indicated amino acid substitutions were engineered into an infectious SFV-GFP-CHIKV
chimeric virus for analysis of resistance or sensitivity to neutralization. Viruses denoted
as “resistant” were not neutralized appreciably by the indicated MAbs, whereas viruses
marked “sensitive” showed no greater than a 2-fold difference in EC50 values compared
to the parent virus. Results are from two to four independent dose-response experiments
performed in duplicate with nine serial dilutions of each MAb.
Table S3. List of VH and VL nucleotide and corresponding amino acid sequences
of CHK-102, CHK-152, CHK-166, and CHK-263 mouse MAbs.
Table S4. Primers used for sequencing and amplifying the structural genes of
CHIKV-LR 2006-OPY1.
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SUPPLEMENTAL METHODS
Humanization of CHK-152. To construct a humanized version of CHK-152, a
cDNA encoding the CDR from the VH and VL variable domains were amplified from
hybridoma cell RNA by a 5' RACE procedure and grafted onto the homologous human
VH (1-18) and Vκ (L-6) backbones. The resulting humanized VH and VL were combined
with human γ1 and κ constant regions, fused to an IgG signal sequence and inserted into
a pCI-neo cassette to construct the heavy and light chain expression plasmids.
Competition ELISA Polystyrene 96-well plates were coated overnight at 4°C
with 5 µg/ml of CHK-65 MAb in sodium carbonate buffer (pH 9.3). Plates were washed
three times in PBS with 0.02% Tween 20 and blocked for one hour at 37°C with PBS,
2% BSA, and 0.02% Tween 20. 3 X 106 FFU of CHIKV 181-25 (gift of R. Tesh,
Galveston, TX) was captured, and plates were washed four times with PBS with 1% BSA
and incubated with murine MAbs for one hour. After washing, plates were incubated
with 125 ng/ml hu-CHK-152 in PBS with 1% BSA. Plates were washed and biotinlabeled goat anti-human secondary antibody (Jackson Labs) was added for one hour.
After washing and incubation with HRP-conjugated streptavidin (Vector Laboratories),
plates were developed with tetramethylbenzidine substrate (Dako). The reaction was
stopped with the addition of 2 N H2SO4, and emission (450 nm) was read using an iMark
microplate reader (Bio-Rad).
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Table S1. List of anti-CHIKV MAbs.
MAb

a

CHK1
CHK2
CHK3
CHK4
CHK5
CHK6
CHK7
CHK8
CHK9
CHK10
CHK11
CHK12
CHK13
CHK14
CHK15

b

Isotype

E2

IgG2c

No

IgG2c

No

IgG2c

weak

IgG2c

Yes

IgG2b

Yes

IgG2c

Yes

IgG3

weak

IgG2c

No

IgG2c

Yes

IgG2c

No

IgG2c

Yes

IgG2c

No

IgG1

Yes

IgG2c

Yes

IgM

No

MAb

Isotype

E2

MAb

Isotype

E2

MAb

CHK-

IgG2c

Yes

CHK-

IgG1

Yes

CHK-

59
CHK-

127
IgG2c

CHK-

Yes

60
CHK-

IgG2c

CHK-

Yes

IgG2c

CHK-

Yes

IgG2b

CHK-

Yes

CHK-

Yes

64
CHK-

IgG2c

CHK-

Yes

IgG2c

CHK-

Yes

CHK-

IgG2c

CHK-

Yes

IgG2c

CHK-

Yes

IgG1

CHK-

Yes

CHK-

Yes

69.B
CHK-

IgG2c

CHK-

Yes

IgG2c

CHK-

Yes

IgG1

Yes

IgG2c

CHK-

Yes

147

82

CHK211

IgG2c

Yes

CHK212

IgG2c

Yes

CHK213

IgG2c

Yes

CHK214

IgG2c

Yes

IgG2c

Yes

CHK216

IgG3

No

CHK217

IgG2c

Yes

CHK218

IgG2c

Yes

CHK219

IgG2b

Yes

E2

IgG1

No

N.D.

N.D.

IgM

No

N.D.

N.D.

N.D.

N.D.

N.D.

N.D.

N.D.

N.D.

IgG2c

No

N.D.

N.D.

IgM/IgG2b

No

N.D.

N.D.

IgM

No

N.D.

Yes

N.D.

N.D.

N.D.

N.D.

CHK215

145

72

CHK210

144

71
CHK-

Yes

143

70
CHK-

IgG2b/c

142
IgG2c

CHK209

141

69.A
CHK-

Yes

140

68
CHK-

IgG2c

138

67

CHK208

135

66
CHK-

Yes

134

65
CHK-

IgG2b

133
IgG2c

CHK207

131

63
CHK-

Yes

130

62
CHK-

IgG2c

129

61
CHK-

206

Isotype

CHK220

CHK16
CHK17
CHK18
CHK19
CHK20
CHK21
CHK22
CHK-

N.D.

N.D

IgG2c

Yes

IgG2c

No

IgG2c

No

N.D.

N.D

IgM

No

IgG2b

No

N.D

N.D

23

CHK25
CHK26
CHK27
CHK28
CHK29
CHK30
CHK31
CHK-

IgG2c

CHK-

Yes

73
CHK-

148
IgG2c

CHK-

Yes

74
CHK-

149
IgG1

CHK-

Yes

75
CHK-

150
IgG1

CHK-

Yes

76
CHK-

IgG2c

CHK-

Yes

77
CHK-

IgG2b

CHK-

Yes

No
IgG1/IgM

CHK-

IgM/IgG1

CHK-

Yes

Yes

N.D

N.D

N.D

No

N.D

No

N.D

No

IgM

No

N.D

No

N.D

No

CHK-

IgG2c

CHK-

Yes

155
IgG2c

CHK-

Yes

156
IgG2c

CHK-

Yes

83
CHK-

157
IgG2c

CHK-

Yes

84
CHK-

158
IgG2c

CHK-

Yes

85
CHK-

159
IgG2c

CHK-

Yes

86
CHK-

160
IgG1

CHK-

Yes

87
CHK-

161
IgG2c

CHK-

Yes

88
CHK-

162
IgG2b

CHK-

Yes

89
CHK-

Yes

IgG2b

Yes

IgG2c

Yes

163
IgM

CHK-

No

83

CHK222
CHK223
CHK224
CHK225

IgG2c

No

CHK226

N.D.

N.D.

CHK227

N.D.

N.D.

154

82

IgG2c

IgG2c

153

79
CHK-

Yes.

152

78
CHK-

IgG2c

151

81

CHK24

CHK-

CHK228

IgG2c

Yes

IgG2b

Yes

IgG2b

Yes

IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

CHK229
CHK230
CHK231
CHK232
CHK233
CHK234
CHK235
CHK237
CHK238
CHK-

IgG1

No

IgM

No

N.D.

N.D.

IgM

No

IgM

No

N.D.

N.D.

N.D.

N.D.

IgG1/IgM

No

IgG1

No

IgG2c

No

IgM

No

IgM

No

IgG1

No

IgG1

No

IgM

No

IgM

No

IgM

weak

32
CHK33
CHK34
CHK35
CHK36
CHK37
CHK38
CHK39
CHK40
CHK41
CHK42
CHK43
CHK44
CHK45
CHK46
CHK47
CHK48
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IgG2c

No

IgM

No

N.D

No

N.D

Yes

N.D

No

IgG2c

No

N.D

N.D

IgG3

No

N.D

N.D

N.D

N.D

N.D

N.D

N.D

N.D

N.D

N.D

IgG3

No

N.D

N.D

IgG2c

Yes

CHK-

164
IgG2c

CHK-

Yes
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CHK-

165
IgG2c

CHK-

No

92
CHK-

166
IgG2c

CHK-

Yes

94
CHK-

168
IgG2c

CHK-

Yes

95
CHK-

169
IgG2c

CHK-

Yes

96
CHK-

170
IgG2c

CHK-

Yes

97
CHK-

172
IgG2c

CHK-

Yes

98
CHK-

173
IgG2c

CHK-

Yes

99
CHK-

174
IgG2b

175
IgG2c

CHK-

Yes

102
CHK-

176
IgM

CHK-

No

103
CHK-

177
IgG2c

CHK-

Yes

104
CHK-

178
IgG1

CHK-

Yes

105
CHK-

179
IgG2c

CHK-

Yes

106
CHK-

180
IgG2c

CHK-

Yes

107
CHK-

181
N.D.

IgG2c

Yes

IgG2c

No

IgG2c

Yes

IgG2c

Yes

IgG1

No

IgG2c

Yes

IgG2c

Yes

IgG2b

Yes

IgG2c

Yes

IgG2c

No

IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

IgG1

Yes

N.D.

No

CHK-

Yes
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239

CHK-

No
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182
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CHK240
CHK241
CHK242
CHK243
CHK244
CHK245
CHK246
CHK247
CHK248
CHK249
CHK250
CHK251
CHK256
CHK261
CHK262
CHK263

IgM

No

N.D.

N.D.

N.D.

N.D.

N.D.

Yes

IgG2c

Yes

N.D.

weak

IgG2c

Yes

IgG2c

Yes

N.D.

N.D.

N.D.

N.D.

N.D.

N.D.

IgG2c

Yes

IgM

No

N.D.

No

IgG2c

Yes

IgG2c

Yes

CHK49
CHK50
CHK51
CHK52
CHK53
CHK54
CHK55
CHK56
CHK57
CHK58

N.D

No

N.D

N.D

N.D

N.D

IgG1

No

IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

CHK-

IgG1

CHK-

Yes

109
CHK-

186
IgG2c

CHK-

Yes

110
CHK-

187
IgG2c

CHK-

Yes

112
CHK-

188
IgG2c

CHK-

No

114
CHK-

189
IgG2c

CHK-

Yes

117
CHK-

190
IgG2c

CHK-

Yes

119
CHK-

191
IgM

CHK-

No

122
CHK-

193
IgG2c

CHK-

Yes

124
CHK-

201
N.D.

CHK-

No

125
CHK-

204
N.D.

CHK-

No

126

205
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IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

IgG2c

Yes

IgG1

Yes

IgG2b

Yes

IgG2b

No

CHK264
CHK265

IgG2c

Yes

IgG2c

Yes

IgG2c/IgG1

Yes

IgG2c

Yes

IgG2c

Yes

IgG2b

No

IgG2c

Yes

CHK266
CHK267
CHK268
CHK269
CHK270

Table S2. Cross-neutralization of infection by wild type and mutant SFV-CHIKV
infection with anti-CHIKV MAbs

Selecting

CHIKV

MAb

variant

Test MAb

Test MAb

Test MAb

Test MAb

CHK-102

CHK-152

CHK-166

CHK-263

CHK-102

E2 L210P

Resistant

Sensitive

N.D.

Resistant

CHK-102

E2 G209E

Resistant

Sensitive

N.D.

Resistant

CHK-152

E2 D59N

Sensitive

Resistant

N.D.

Sensitive

CHK-152

E2 A89E

Sensitive

Sensitive

N.D.

Sensitive

CHK-166

E1 K61T

N.D.

N.D.

Resistant

N.D.

CHK-166

E1 P74A

N.D.

N.D.

Sensitive

N.D.

CHK-263

E2 K215E

Resistant

Sensitive

N.D.

Resistant
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Table S3. VH and VL nucleotide and protein sequences of protective anti-CHIKV MAbs
A. CHK-102
CHK-102-VH
atgggatggagctgtatcatgttcttcctcctgtcaggaactgcaggtgtccaatccCAGGTTCAGCTGCAGCAG
TCTGGGGCTGAGCTGGTGAAGCCTGGGGCCTCAGTGAAGATTTCCTGCAAAA
CTTCTGGCTACGCATTCAGTAGTTTCTGGATGCACTGGGTGAAGCAGAGGCCT
GGAAAGGGTCTTGAGTGGATTGGACAGATTTATCCTGGAGATGGTGATACTA
ACTATAACGGAAAGTTCAAGGACAAGGCCACACTGACTGCAGACAAATCCTC
CAACACAGCCTACATGCAGCTCACCAGCCTGACCTCTGAGGACTCTGCGGTC
TATTTCTGTGCAAGAAACTTACTTTTTGACTACTGGGGCCAAGGCACCACTCT
CACAGTCTCCTCA
MGWSCIMFFLLSGTAGVQSQVQLQQSGAELVKPGASVKISCKTSGYAFSSFWMH
WVKQRPGKGLEWIGQIYPGDGDTNYNGKFKDKATLTADKSSNTAYMQLTSLTS
EDSAVYFCARNLLFDYWGQGTTLTVSS
CHK-102-VL
GAGATCCTGATGACTCAGTCTCCAGCCATCCTGTCTGTGAGTCCAGGAGAAA
GAGTCAGTTTCTCCTGCAGGGCCAGTCAGAGCATTGGCTCAAACATACACTG
GTATCAGCAAAGAACAAATGGTTCTCCAAGGCTTCTCATAAAGTATGCCTCT
GAGTCTATCTCTGGGATCCCTTCCAGGTTTAGTGGCAGTGGGTCAGGGACAG
ATTTTACTCTTAGCATCAACAGTGTGGAGTCTGAAGATATTGCAGATTATTAC
TGTCAACAGAATAATATCTGGCCATTCACGTTCGGCTCGGGGACAAAGTTGG
AAATAAAG
EILMTQSPAILSVSPGERVSFSCRASQSIGSNIHWYQQRTNGSPRLLIKYASESISGI
PSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNIWPFTFGSGTKLEIK

B. CHK-152
CHK-152-VH
atgggatggagctgtatcatcctcattttggtagcagcagctacaggtgtccactccCAGGTCCAGCTGCAGCAG
CCTGGGGCTGCGCTTGTGAAGCCTGGGGCTTCAGCGATGATGTCCTGCAAGG
CTTCTGGCTACACCTTCACCAGCTACTGGATAACCTGGGTGAAGCAGAGGCC
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TGGACAAGGCCTTGAATGGATTGGGGACATTTACCCTGGTACTGGTCGAACT
ATCTACAAGGAGAAGTTCAAGACCAAGGCCACACTGACTGTAGACACATCCT
CCAGCACAGCCTTCATGCAGCTCAACAGCCTGACATCTGAGGATTCAGCGGT
CTATTACTGTGCAAGAGGCTACGGTAGTCCTTACTATGCTTTGGACTACTGGG
GTCAAGGAACCTCAGTCACCGTCTCCTCA
MGWSCIILILVAAATGVHSQVQLQQPGAALVKPGASAMMSCKASGYTFTSYWIT
WVKQRPGQGLEWIGDIYPGTGRTIYKEKFKTKATLTVDTSSSTAFMQLNSLTSED
SAVYYCARGYGSPYYALDYWGQGTSVTVSS
CHK-152-VL
atggagacagacacaatcctgctatgggtgctgctgctctgggttccaggctccactggtGACATTGTGCTGACCC
AATCTCCAGCTTCTTTGGCTGTGTCTCAAGGGCAGAGGGCCACCATCTCCTGC
AAGGCCAGCCAAAGTGTTGATTATGATGGTGATAGTTATGTGAACTGGTACC
AACAGAAACCAGGACAGTCACCCAAACTCCTCATCTATGATGCATCCAATCT
AGAATCTGGGATCCCAGCCAGGTTTAGTGGCAGTGGGTCTGGGACAGACTTC
ACCCTCAACATTCATCCTGTGGAGGAAGAGGATGTTGCAACCTATTACTGTCA
GGAAAGTAATGAGGATCCTCGGACGTTCGGTGGAGGCACCAAGCTGGAAATC
AAA
METDTILLWVLLLWVPGSTGDIVLTQSPASLAVSQGQRATISCKASQSVDYDGDS
YVNWYQQKPGQSPKLLIYDASNLESGIPARFSGSGSGTDFTLNIHPVEEEDVATY
YCQESNEDPRTFGGGTKLEIK

C. CHK-166
CHK-166-VH
atgaacttggggctcagcttgattttccttgtccttgttttaaaaggtgtccagtgtGAAGTGAGGCTGGTGGAGT
CTGGGGGAGGCTTAGAGCAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGC
CTCTGGATTCACTTTCAGTGACTATTTCATGTATTGGGTTCGCCAGACTCCAG
AGAAGAGGCTGGAGTGGGTCGCATATATTAGTAATGGTGGTATTAGTACCTT
TTATTCAGACGCTGTTAAGGGCCGATTCACCATCTCCAGAGACAATGCCAGG
AACACCCTATACCTACAAATGAGTCGTCTGAAGTCTGAGGACACAGCCATAT
ATTACTGTGTAAGACAGGTCTACGGTCAGGGCTACTTTGACTACTGGGGCCA
AGGCACCACTCTCGCAGTCTCCTCA
MNLGLSLIFLVLVLKGVQCEVRLVESGGGLEQPGGSLKLSCAASGFTFSDYFMY
WVRQTPEKRLEWVAYISNGGISTFYSDAVKGRFTISRDNARNTLYLQMSRLKSE
DTAIYYCVRQVYGQGYFDYWGQGTTLAVSS
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CHK-166-VL
atggattttcaggtgcagattttcagcttcctgctaatcagtgcctcagtcataatgtccagaggaCAAATTGTTCTCAT
CCAGTCTCCAGCGATCATGTCTGCGTCTCTAGGGGAACGGGTCACCATGACC
TGCACTGCCAGCTCAAGTGTAAGTTCCAGTTACTTGCACTGGTACCAGCAGA
AGCCAGGATCCTCCCCCAAACTCTGGATTTATAGTTCATTCAGCCTGGCTTCT
GGAGTCCCAGCCCGGTTCAGTGGCAGTGGATCTGGGACCTCTTACTCTCTCAC
AATCAGCACCATGGAGGCTGAAGATGCTGCCACGTATTACTGCCACCAGTAT
TTGCGTTCCCCGTGGACGTTCGGTGGAGGCTCCAAGCTGGAAATCAAA
MDFQVQIFSFLLISASVIMSRGQIVLIQSPAIMSASLGERVTMTCTASSSVSSSYLH
WYQQKPGSSPKLWIYSSFSLASGVPARFSGSGSGTSYSLTISTMEAEDAATYYCH
QYLRSPWTFGGGSKLEIK

D. CHK-263
CHK-263-VH
atggaatggcctttgatctttctcttcctcctgtcaggaactgcaggtgtccaatccCAGGTTCAGCTGCAGCAGT
CTGGGGCTGAGCTGGTGAAGCCTGGGGCCTCAGTGAAGATTTCCTGCAAAGC
TTCTGGCTACGCATTCAGTAGCTACTGGATGAACTGGGTGAAGCAGAGGCCT
GGAAAGGGTCTTGAGTGGATTGGACAGATTTATCCTGGAGATGGTGATACTA
ACTACAACGGAAAGTTCAAGGGCAAGGCCACACTGACTGCAGACAAATCCTC
CAGCACAGCCTACATGCAGCTCAGCAGCCTGACCTCTGAGGACTCTGCGGTC
TATTTCTGTGCAAGAGGAGGTCTAACTATTGACTACTGGGGCCAAGGCACCA
CTCTCACAGTCTCCTCA
MEWPLIFLFLLSGTAGVQSQVQLQQSGAELVKPGASVKISCKASGYAFSSYWMN
WVKQRPGKGLEWIGQIYPGDGDTNYNGKFKGKATLTADKSSSTAYMQLSSLTS
EDSAVYFCARGGLTIDYWGQGTTLTVSS
CHK-263-VL
atggtatccacacctcagttccttggacttatgcttttttggatttcagcctccagaggtGATATTGTACTGACTCAG
TCTCCAGCCACCCTGTCTGTGACTCCAGGAGATAGCGTCAGTCTTTCCTGCAG
GGCCAGCCAAAGTATTAGCGACAACCTACACTGGTATCAACAAAAATCACAT
GAGTCTCCAGGGCTTCTCATCAAGTATGCTTCCCAGTCCATCTCTGGGATCCC
CTCCAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACTCTCAGTATCAAC
AGTGTGGAGACTGAAGATTTTGGAATGTATTTCTGTCAACAGAGTAACAGCT
GGCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA
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MVSTPQFLGLMLFWISASRGDIVLTQSPATLSVTPGDSVSLSCRASQSISDNLHW
YQQKSHESPGLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSN
SWPYTFGGGTKLEIK

The VH and VL variable domains were amplified from hybridoma cell RNA by a 5'
RACE procedure. Underlined nucleotides and amino acids correspond to the signal
sequences, when obtained.
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Table S4. Primers used for sequencing and amplifying the structural genes of CHIKVLR 2006-OPY1.
Sequencing Primer

5'-Sequence-3'

1: 5'-8248F

GTCTTAGGAGGAGCTAATGAAGGAG

2: 5’-8573F

CCACAAGACCATACTTAGCTCACTGTCC

3: 5'-8912F

CATGTACGCACCCATTTCACC

4: 5'-9224F

CGGTCACCAATCACAAAAAGT

5: 5'-9500F

CCGTGCCGACTGAAGGG

6 5'-9802F

GCTAAAGCGGCCACATACC

7: 5'-10101

CACTTTGGAGCCAACACTATCG

8: 5'-10389

GCTCCGCGTCCTTTACCA

9: 5'-10676

CGGTACACGTGCCATACTCTCAGG

10: 5'-11017

GCTGAGATAGAAGTTGAAGGGA

PCR Primer

5'-Sequence-3'

5'-8248F

GTCTTAGGAGGAGCTAATGAAGGAGCCCGT

5'-11359R

GTGTGTCTCTTAGGGGACACATATACCTTCATACTT
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Chapter III
Conclusions and Future Directions
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Conclusions
In this study, we have identified, cloned, and begun characterization of 230 novel CHIKV
MAbs produced from mice immunized with the epidemic strain, CHIKV-LR 2006 OPY1.
Thirty-six of these MAbs are neutralizing; over half of them potently inhibit strains representing
all three distinct genotypes of CHIKV. Many of these MAbs were protective in both a lethal and
arthritis model of CHIKV infection and four MAbs (CHK-102, CHK-152, CHK-166 and CHK263) prophylactically protected all IFNAR-/- mice against death. We sought to define the
functional epitopes of highly neutralizing anti-CHIKV MAbs and to identify correlates of
humoral protection. To functionally map protective MAbs, we selected for escape mutants in
vitro and also isolated mutant CHIKVs in vivo.
We characterized the first MAb targeting the E1 glycoprotein of CHIKV (CHK-166);
although this MAb was not as potently neutralizing in vitro, it was still highly effective in vivo. It
binds to domain II of E1, adjacent to the conserved fusion loop. CHK-102 and CHK-263 target
domain B of E2; escape mutants selected against one of these two MAbs were always
reciprocally resistant. Combination therapy with CHK-102 and CHK-263 was not more effective
than monotherapy, further supporting our hypothesis that MAb therapy targeting different
epitopes is protective because it prevents the emergence of escape mutants. We determined that
our most potent MAb, CHK-152, inhibits fusion of CHIKV with lipid membranes and targets
domain A of E2. Although neutralization alone can protect the majority of mice when an
aglycosyl N297Q variant of CHK-152 (lacking the ability to engage effector functions) is
administered, it is still more protective when effector functions are recruited, especially at lower
doses of MAb. While CHK-152 neutralization was not enhanced by CHK-102, CHK-166 or
CHK-263 in vitro, its protective capacity was certainly augmented in vivo. Indeed, combination
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monoclonal antibody therapy with MAbs that target different epitopes on E1 and E2 was
protective against CHIKV-induced death in IFNAR-/- mice.
With the globalization of diseases and spread of mosquito vectors, the need for
development of a CHIKV vaccine has increased. Currently, no licensed human vaccine exists for
CHIKV and mosquito control is the only reliable means of preventing infection. Since sera from
convalescent CHIKV infected patients or CHIK virus-like particle (VLP) vaccinated primates
can prevent and cure an otherwise lethal infection in IFNAR-/- mice [1,2], we believe an epitopedirected vaccine may be possible. This study leaves us with many exciting questions and
directions, some of which we have begun to address.
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Future Directions
There are 29 different alphaviruses distributed throughout the world; the Semliki Forest
virus antigenic complex consists of CHIKV and seven other related alphaviruses [3]. Many are
endemic in Africa and Asia, where CHIKV epidemics have been reported for centuries. CHIKV
is serologically most closely related to O’nyong’nyong virus (ONNV), which causes a similar
debilitating, arthritic fever. In fact, the term “O’nyong’nyong” describes a weakening of the
joints in the Nilotic language of Uganda where an epidemic began in the late 1950s and spread of
many neighboring countries, affecting about two million people [4]. ONNV and CHIKV are
similar genetically and share 72% nucleotide homology and 87% amino acid homology [5] but
phylogenetic analysis indicates that these two viruses probably diverged thousands of years ago
[6]. Additionally, ONNV is the only alphavirus transmitted by Anopheles mosquitoes, which are
widely known as the vector for transmission of malaria-causing Plasmodium species [7]. Mayaro
virus causes a disease indistinguishable from that caused by ONNV, but has been found only in
South America, or in travelers returning from this region [6,8].
Based on the antigenic and phylogenetic relatedness of many of these alphaviruses to
CHIKV (Figure 1), it is possible that some of our CHIKV MAbs cross-react with or even
neutralize some of these other alphaviruses. We began to study this by growing stocks of ONN,
Ross River, Semliki Forest, Mayaro, Una, Getah, Bebaru, Middleburg, Barmah Forest, Sindbis
and Venezuelan equine encephalitis viruses. We tested for cross-reactivity between the 36
neutralizing CHIKV MAbs and two non-neutralizing MAbs against the eleven alphaviruses by
flow cytometry, as described in the methods. We also tested another strain of CHIKV, CHIKVRoss, representing the ECSA genotype prior to the emergence of La Reunion epidemic strain,
which is known to contain many mutations in the structural genes. All of the MAbs, including
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the non-neutralizing MAbs CHK-84 and CHK-141 cross-reacted with CHIKV-Ross (Figure 2).
CHK-266 was the only MAb tested that failed to bind to one of the strains of CHIKV; it showed
no reactivity to CHIKV-RSU1, the Asian strain, and also did not cross-react to any of the other
alphaviruses. The epitope for this MAb appears to be restricted to the African lineage of
CHIKVs and will be interesting to explore further with mapping studies.
Seventeen of the neutralizing MAbs strongly cross-reacted (50-100% of infected cells
bound MAb as judged by flow cytometry) and ten moderately cross-reacted (10-50% of infected
cells bound MAb) with ONNV. As demonstrated previously, CHK-263 and CHK-102 are both
potent, protective E2 domain B MAbs, as determined by functional mapping experiments;
however, CHK-102 strongly cross-reacts with ONNV but CHK-263 does not recognize ONNV.
Neither of these MAbs binds to any of the other alphaviruses tested. It will be interesting to
further explore how the epitopes for these two MAbs differ since they both neutralize all three
strains of CHIKV (LR, RSU1 and IbH35) with comparable potency and completely protect
IFNAR-/- mice prophylactically against CHIKV-LR infection at the 100 µg dose. However,
CHK-263 is more protective than CHK-102; this is apparent when lower doses are used. Perhaps
the CHIKV epitope specificity of this MAb contributes to its enhanced protective potential.
Neutralization of ONNV should be explored by performing neutralization assays with the MAbs
that cross-react with this virus. This may lend insight into the functional significance of shared
epitopes between these two related alphaviruses.
Just a few of the CHIKV neutralizing MAbs cross-reacted with seven or more of the
alphaviruses tested: CHK-166, CHK-180, CHK-187 and CHK-265 (Figure 2). Cross-reactivity
with many such diverse viruses suggests that these four MAbs target an epitope that is conserved
amongst the alphaviruses. From escape mutant analysis we know that CHK-166 binds to a highly
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conserved region of domain II of E1. Further studies into CHK-180, CHK-187 and CHK-265
may define other highly conserved alphavirus epitopes. Neutralization experiments performed by
our collaborators (Ted Pierson, NIH, unpublished data) demonstrate that CHK-65, CHK-77,
CHK-88 and CHK-124 also neutralize Semliki Forest virus (SFV) in a dose-dependent fashion.
They did not test CHK-187, which is the only other strongly cross-reactive MAb against SFV.
These results are exciting because all of the MAbs tested that efficiently cross-reacted to SFV
also neutralized infection. This suggests that it may be promising to test the other alphaviruses
that strongly bind CHK MAbs for neutralization potential.
Cross-reactivity appears to correlate with the genetic relatedness of the alphaviruses.
Middleburg and Barmah Forest viruses are assigned to two separate antigenic complexes and
displayed only limited cross-reactivity with these CHK-MAbs. Only two MAbs, CHK-96 and
CHK-98, moderately cross-react with Venezuelan equine encephalitis virus (VEEV), a more
distantly related New World Alphavirus.
It also will be informative to functionally map all of the neutralizing anti-CHIKV MAbs
and develop a more global structural picture of neutralization. We have begun working on this by
using an NNN codon mutagenesis strategy. Primer pairs incorporating NNN at the amino acid of
interest will be designed, so there will be 64 primer pairs per amino acid selected. Theoretically
speaking, to completely map these antibodies we would need to make NNN mutations for each
codon of the 1,100 amino acids in E1, E2 and E3 by designing and using an NNN primer set for
every amino acid. We can target candidate amino acids by choosing those that fulfill certain
characteristics including high conservation amongst alphaviruses, variation among CHIKV
strains, or surface exposed or hydrophilic residues based on existing crystal and cryo-electron
microscopy structures [9,10]. It is possible that rare MAbs inhibit infection by binding to regions
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that are exposed only at certain times in the viral replication cycle, such as homo-trimerization or
the removal of the E2-Domain B cap from the fusion loop. The relevance of these regions in
neutralization may be missed if only surface exposed residues are selected, so it may be prudent
to revisit mapping of any MAbs that were unaffected by the amino acids initially mutated.
In preliminary experiments, we screened 38 anti-CHIKV MAbs against CHIKV encoding
a point mutation (see methods) that conferred resistance to CHK-152 or CHK-166 (E2: D59N
and E1: K61T, respectively); these mutant viruses were tested first since CHK-152 and CHK166 were the most protective in vivo. We were interested in determining whether any of the other
MAbs in our repertoire require either of these residues and perhaps share an epitope with these
potent MAbs. While none of the 38 MAbs (besides CHK-152) were incapable of neutralizing
CHIKV-D59N, CHK-180 and CHK-269 were unable to neutralize CHIKV-K61T, even at a high
MAb concentration of 10 µg/mL. This indicates that residue K61T also is important for efficient
neutralization by CHK-180 and CHK-269. Since CHK-166 and CHK-180 have identical crossreactivity and neutralization profiles, it is possible that they share a large portion of their epitope.
Further study into the antibody response of seropositive, asymptomatic individuals also is
warranted. Most people that are infected with CHIKV develop acute symptoms of disease,
including fever, arthralgia, and myalgia. However, small subsets of people have been identified
on La Reunion and in Kerala, India, that are seropositive for CHIKV but failed to develop
symptoms consistent with CHIKV disease [11,12]; this indicates that prevalence of
asymptomatic, seropositive people is not regionally restricted. It will be interesting to investigate
the quality and kinetics of the antibody response generated by asymptomatic individuals. It is
possible that they produced highly neutralizing antibodies that, in conjunction with a rapid innate
immune response, clear CHIKV before the infection became fully established. CHIKV spreads
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widely in naïve populations; on the island of La Reunion over a third of the population
(~300,000 people) was infected, so identifying seropositive, asymptomatic individuals should be
straightforward [13-15]. It is also possible that asymptomatic individuals lack a necessary cofactor or receptor in particular cells (akin to a CCR5∆30 mutation in patients exposed to HIV
who do not develop disease), which may render the environment resistant to CHIKV infection.
Another possible explanation for why a subset of people did not exhibit any apparent clinical
symptoms of CHIKV disease is that they previously generated cross-reactive antibodies against a
related alphavirus. In this case, upon CHIKV infection, memory B cells would re-activate,
differentiate, and secrete antibodies that help to rapidly clear infection. A complete history of
febrile, arthritic diseases and the persistence of previous joint pain in this population will be
important to note. Nevertheless, it may be informative to understand how the antibody response
of asymptomatic, seropositve people differed from those that became ill. Epitopes targeted by
potent antibodies in the former may help inform vaccine design.
Examining differences between the antibody responses of patients that do or do not
develop chronic arthritis also may be enlightening. Patient studies have correlated a more severe,
acute disease with early, high viremia but this group also developed an early IgG3 response and
completely cleared CHIKV infection without persistent arthralgia [16]. In fact, none of the
patients producing early IgG3 (7- 10 days after the onset of infection) in this study developed
persistent arthrlagias, but 30% of late IgG responders did [16]. While acute CHIKV is a painful
and debilitating illness, it is usually self-limited and resolves within two weeks; arguably, the
most significant morbidity occurs during the chronic stages, during which symptoms may linger
and recur for months to years. While kinetics of the antibody response appear to contribute to
disease pathogenesis or restriction, the quality of this response may be important. Further
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investigation into epitopes targeted by late IgG responders that do not develop chronic illness
may be informative. B cells from consenting, convalescent patients with a history of persisting
arthralgias and with no chronic illness could be harvested and immortalized so that the
neutralization potential of their antibody response and epitopes targeted by these MAbs can be
studied.
CHK-152 or CHK-166 completely protected IFNAR-/- mice prophylactically, but a lower
dose of CHK-152 protected 75% of mice. A lower dose of CHK-166, however, failed to protect
any mice, and they all died at 7 days post infection. Independently, CHK-152 and CHK-166
were partially protective when administered one day post CHIKV infection. We identified
CHIKV escape mutants, including the E2-D59N mutation, in the leg muscle and brains of mice
that died despite CHK-152 treatment, but only sequenced wild-type virus from tissues harvested
from mice prophylactically treated with CHK-166. Tissue was harvested from one mouse that
died despite CHK-166 therapeutic treatment, and we discovered a novel mutation that conferred
complete resistance to neutralization by CHK-166, E1-G64S. When we selected for escape
mutants to CHK-166 in vitro, all plaques sequenced featured the mutation E1-K61T; however,
this mutation was not isolated in vivo. Combination therapy with CHK-166 and CHK-152 was
completely protective earlier in the course of infection in IFNAR-/- mice, but less effective when
administered 24 to 36 hours before death. However, our sequencing studies from mice dying
despite combination therapy never defined a double mutant (ie D59N + K61T) or a novel
mutation conferring complete resistance to the respective MAbs. As such, we have begun to test
the potential fitness costs of the E2-D59N, E1-K61T and E2-D59N + E1-K61T mutations on
CHIKV. To assess this, we introduced these mutations into CHIKV-LR 2006 OPY1 infectious
clone, to generate isogenic viruses. After generating passage 0 stocks by electroporation of
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mammalian cells and passage 1 insect cell stocks, we have begun performing growth curves on
mammalian and insect cells. We have not observed any difference in the growth of the D59N or
K61T viruses, but studies are ongoing. We are being careful to maintain the cells in medium
containing CHK-152, CHK-166 or both CHK-152 and CHK-166 to prevent reversion to the
wild-type virus.
Fitness experiments also have been performed in mice, and while all three viruses
(delivered to mice that were treated with the respective MAb to prevent reversion and to
untreated mice) are lethal in the IFNAR-/- model, the mice infected with the double mutant and
treated with CHK-152 and CHK-166 survived a few days longer before succumbing to death
(data not shown). This suggests that in vivo, there may be a fitness cost to CHIKV for
maintaining both these mutations. Collaboratively, with the Higgs laboratory, we are testing the
effect of these three mutations on CHIKV fitness in their Aedes mosquito vector. Unlike other
viruses, arboviruses undergo unique selective pressure that occurs with infection of vertebrate
and invertebrate hosts. As such, fewer mutations are generally observed amongst alphavirus
genomes than in other RNA viruses [17], presumably due to purification of genomic changes
that yield fitness costs in a given species. We are interested in investigating whether these
mutations that confer resistance to MAbs CHK-152 and CHK-166 are purified in mosquito
populations; this has important implications for possible MAb-based therapy. It has previously
been shown that Aedes albopictus midgut infectivity was enhanced by a single point mutation
E1-A226V [18] and that aspartic acid (D) at amino acid 60 on E2 is an important determinant of
Aedes aegypti and Aedes albopictus infectivity [19]. This latter mutation is directly adjacent to
E2-D59N mutation that we are testing.
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As another step towards a potential combination MAb therapy for patients, therapeutic
treatment of non-human primates was performed by our collaborators (Dan Streblow, OHSU).
These studies show a decrease in viremia and viral dissemination after treatment with CHK-152
and CHK-166. Thus, it is possible that there could be a future role of MAb based prophylaxis or
therapy in target populations including pregnant women, infants, and patients with certain preexisting co morbidities that are vulnerable to serious CHIKV-induced complications [20-23].
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Materials and methods
Cross-reactivity of CHIKV antibodies. CHIKV MAbs were tested for cross-reactivity
against a panel of non-CHIKV arthritogenic alphaviruses available from the World Arbovirus
collection (generous gift of R. Tesh, Galveston, TX) and a single New World encephalitic
alphavirus. This panel included the following viruses, which were passaged once in Vero76 or
Vero T144 cells: Una (CO AR), Mayaro (BE H 407), Semliki Forest (M4862), Sindbis (AR339),
Getah (AMM-2021), Barmah (K 10521), O'nyong-nyong (MP30), Middleburg (30037), Ross
River (T48) and Venezuelan equine encephalitis (TC-83) viruses. Vero cells were infected with
each virus (MOI of 0.01 for 12 to 24 hours, depending on the virus), harvested with HBSS
supplemented with 3 mM EDTA, fixed with 1% PFA in PBS for 8 minutes, and permeabilized
with 0.1% (w/v) saponin detergent solution in HBSS. Approximately 105 cells were incubated
with different CHIKV MAbs (10 µg/mL solution) for 60 minutes on ice. After washing, cells
were then incubated with 4 µg/mL of Alexa 647 anti-mouse IgG secondary antibody
(Invitrogen), evaluated on a FACSArray flow cytometer (Becton-Dickinson) and analyzed using
FlowJo software (Tree Star).
Cells and viruses. Vero cells and BHK21-15 cells were cultured in DMEM (Dulbecco’s
modified Eagle medium) supplemented with 5% or 10% fetal bovine serum, respectively, (FBS)
(Omega Scientific), 10 mM HEPES, nonessential amino acids (Cellgro) and antibiotics
(penicillin and streptomycin G) at 37oC in a 5% CO2 incubator. C6/36 Aedes albopictus cells
were grown in Leibovitz-15 media (Gibco) supplemented with 10% FBS, 10 mM HEPES, and
antibiotics (penicillin and streptomycin G) at 27oC. The infectious clone of CHIKV LR 2006
OPY-1 (strain 142) was a generous gift from S. Higgs (Galveston, TX). Plasmids containing the
wild-type CHIKV structural genes or single point mutations, CHK struct- pDonor221, were a
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generous gift from T. Pierson (NIAID). Single point mutations were introduced into the
infectious clone by ligating a SgrA1 (New England Biolabs) and Sfi1 (New England Biolabs)
double digested CHK struct- pDonor221fragment containing the respective mutation, into the
SgrA1 and Sfi1 double digested infectious clone. The double mutant D59N+K61T-142 was
created by performing a mutagenesis reaction on the D59N-142 plasmid with primers :
Forward - gtctccgtacgtgacgtgctgcggtacag
Reverse - ctgtaccgcagcacgtcacgtacggagac
To produce virus from infectious clones, plasmids were linearized and RNA was produced using
an SP6 DNA-dependent RNA polymerase transcription kit following the manufacturer’s
instructions (mMessage kit; Ambion). CHIKV RNA was electroporated into BHK21-15 cells
and supernatant was harvested 28 hours later, aliquoted, and frozen at -80oC. C6/36 cells were
infected with this P0 CHIKV-LR at an MOI of 0.01, in the presence of 10 µg/mL of either CHK166 for K61T-142, CHK-152 for D59N-142 and 10 µg/mL of both CHK-166 and CHK-152 for
the D59N+K61T-142 double mutant. Supernatant was harvested 68- 72 hrs later. Virus was
titered on Vero cells by focus forming unit (FFU) assay.

Neutralization assays. MAb neutralization of CHIKV was assessed by an FFU assay.
Eleven three-fold serial dilutions of MAb (ranging from 10 µg/ml to ~1 ng/ml in 2% DMEM)
were incubated with ~102 FFU of CHKV for one hour at 37oC. MAb-virus complexes were
added to a monolayer of African monkey Vero cells (seeded overnight at 3 X 104 cells/well, in
96-well plates) in 5% DMEM. Cells were infected at 37oC for 90 minutes, and overlaid with 1%
(w/v) methylcellulose in Modified Eagle Media (MEM) supplemented with 4% FBS. Plates were
harvested 18 and fixed with 1% (w/v) paraformaldehyde in PBS. The plates were incubated
sequentially with 500 ng/ml of a chimeric CHK-9 MAb (chCHK9) and a 0.3 mg/ml solution of
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HRP-conjugated goat anti-human IgG secondary antibody (Sigma) in PBS supplemented with
0.1% saponin and 0.1% BSA. CHIKV-infected foci were visualized using TrueBlue peroxidase
substrate (KPL) and quantitated on an ImmunoSpot 5.0.37 macroanalyzer (Cellular Technologies
Ltd). Non-linear regression analysis was performed, and EC50 values were calculated using
Prism compared to wells infected with CHIKV in the absence of antibody.

Growth Curves Vero cells were seeded overnight at 6 X 104 cells/well in 12 well plates
in 1mL of DMEM containing 5% FBS. C6/36 cell-derived CHIKV mutants or WT CHIKV were
incubated with 10 µg/mL of CHK-166, CHK-152, both CHK-166 and CHK-152 or no MAb for
1 hour at 37°C. Media was removed from Vero cells and they were infected with 500 µL of
inoculum for 1 hour at 37°C. After the hour, inoculum was removed and cells were washed with
PBS. Media containing the respective MAb or no MAb was added back to the cells. Time points
were harvested at 1, 12, 24 and 36 hours post-infection. Similarly, growth curves were performed
on C6/36 cells with P0 BHK-derived CHIKVs and time points were harvested at 1, 24, 48 and 72
hours post-infection. Virus was titered by FFU assay. Experiments were performed in triplicate
three times.

Mouse Experiments. IFNAR-/- C57BL/6 mice were obtained from J. Sprent (Scripps
Institute, San Diego CA), backcrossed ten times onto the C57BL/6 background, and bred in the
pathogen-free animal facilities of Washington University School of Medicine. Experiments were
performed with the approval of the Washington University Animal Studies Committee. To
prevent mutant CHIKV reversion, some mice were treated pre-exposure with 100 µg of either
CHK-152, CHK-166 or both CHK-152 and CHK-166. MAbs were administered by
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intraperitoneal (IP) injection into 6 to 8 week old IFNAR-/- mice. Twenty-four hours later, mice
were inoculated in the footpad with 10 FFU of C6/36 cell derived D59N-142, K61T-142,
D59N+K61T-142, or CHIKV-LR in 50 µl of Hanks balanced salt solution (HBSS) supplemented
with 1% heat-inactivated FBS.
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Figure Legends

Figure 1. This figure is borrowed from Powers, 2001 [6]. Phylogenetic relationship of most
Alphaviruses species, generated from partial E1 envelope protein sequences. The open circle
adjacent to a branch indicates hypothetical Old to New World introduction, and the closed circle
indicates New to Old World introduction, assuming a New World origin; the open square
indicates Old to New World introduction, and the closed square indicates New to Old World
introduction, assuming an Old World origin of the nonfish Alphavirus clade.

Figure 2. Cross-reactivity of Alphaviruses with 38 anti-CHIKV MAbs. Vero76 cells were
infected at an MOI of 0.01, fixed and permeabilized. These cells were stained with 10 µg/mL of
the anti-CHIKV MAbs. The viruses are listed in order from least to most divergence from
CHIKV-LR. (++) denotes strong binding, 50-100 % of cells stained with this MAb. (+) denotes
moderate binding, 10-50% of cells stained with this MAb. (-) denotes no binding, <10% of cells
bound this MAb. Immune sera refers to a 1:1000 dilution of serum harvested from mice that
were immunized with CHIKV-LR.
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FIGURE 1

From Powers et al, 2001.
FIG. 2. Phylogenetic tree of all Alphavirus species, and selected subtypes and variants, generated from partial E1 envelope glycoprotein gene
sequences by using the neighbor-joining program with the F84 distance formula (61). Virus abbreviations are found in Table 1, footnote 6.
Numbers refer to bootstrap values for clades defined by the adjacent node. The topology of Cabassou virus (CABV) and Pixuna virus (PIXV)
within the VEEV complex was constrained based on the more robust results of the complete structural polyprotein sequence analysis (see Fig. 3),
and this topology was not significantly less likely based on maximum-likelihood analyses with the E1 gene sequences. The open circle adjacent to
a branch indicates hypothetical Old to New World introduction, and the closed circle indicates New to Old World introduction, assuming a New
World origin; the open square indicates Old to New World introduction, and the closed square indicates New to Old World introduction, assuming
an Old World origin of the nonfish Alphavirus clade.

present analyses are also consistent with this hypothesis. Excluding the fish and seal viruses, a New World origin would
require at least three transoceanic introductions between the
hemispheres: (i) transport of the ancestor of the Barmah Forest-Ndumu-Middelburg-Semliki Forest virus complexes from
the New World to the Old World, (ii) transport of the ancestor
of the Sindbis and Whataroa viruses to the Old World, and (iii)
transport of the ancestor of the Mayaro and Una viruses from
the Old World to the New World (Fig. 2). However, an Old
World origin is also consistent with three transoceanic introductions between the hemispheres: (i) transport of the ancestor of the Trocara virus-WEE-EEE-VEE complexes from the
Old World to the New World; (ii) transport of the ancestor of
the Sindbis and Whataroa viruses to the Old World, and (iii)
transport of the ancestor of the Mayaro and Una viruses from
the Old World to the New World (Fig. 2). These equally parsimonious scenarios do not favor either hypothesis over the
other. An ancestral alphavirus presumably adapted to fish in
the distant past to form the SDV-SPDV lineage. The possible
transmission of SESV by insects (lice) strengthens the hypothesis that alphaviruses arose as insect-borne or insect viruses.
Previous estimates placed the origin of the alphaviruses several thousand years ago (73, 79). However, the methods em-

ployed previously relied on the assumption of an equal rate of
substitutions across nucleotide or amino acid positions in the
alphavirus genome. Our data clearly indicate that this assumption is invalid; all estimates of the uniformity of nucleotide
changes across sites are far from uniform, with an average
gamma value of only 0.24 for those viruses examined in detail
(range, 0.05 to 0.31). This nonuniformity in nucleotide substitutions across sites, combined with the saturation of nucleotide
changes in many positions, indicates that estimates on the
order of thousands of years ago for the alphavirus ancestor are
far too recent. An accurate time estimate for the alphavirus
progenitor may be impossible due to these factors. Another example of the problems with estimating internal branch lengths
is illustrated by our analysis of the recombination event between EEEV- and Sindbis virus-like ancestors leading to the
WEEV Fort Morgan virus-Highlands J virus group (19, 80).
The interior branch lengths produced with most of the phylogenetic methods yielded different horizontal positions for the
internal branches shown previously to represent the recombinant ancestors (80) (Fig. 2). The fact that these ancestors did
not occur at the same horizontal position (the dashed line in
Fig. 2 cannot be drawn vertically) indicates error in the internal
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